| 1 |
O'Hagan RC, Heyer J. KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations. Genes Cancer 2011;2:335-43. [PMID: 21779503 DOI: 10.1177/1947601911408080] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 2 |
Van Cutsem E, Li CP, Nowara E, Aprile G, Moore M, Federowicz I, Van Laethem JL, Hsu C, Tham CK, Stemmer SM. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Br J Cancer. 2014;111:2067-2075. [PMID: 25247318 DOI: 10.1038/bjc.2014.494] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 3 |
Kindler HL. Pancreatic cancer: an update. Curr Oncol Rep 2007;9:170-6. [PMID: 17430687 DOI: 10.1007/s11912-007-0018-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 4 |
Barros AG, Pulido CF, Machado M, Brito MJ, Couto N, Sousa O, Melo SA, Mansinho H. Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). Int J Oncol 2021;59:110. [PMID: 34859257 DOI: 10.3892/ijo.2021.5290] [Reference Citation Analysis]
|
| 5 |
Kobayashi S, Ueno M, Irie K, Goda Y, Aoyama T, Morinaga S, Ohkawa S, Morimoto M. Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma. Pancreatology 2015;15:525-30. [PMID: 26255025 DOI: 10.1016/j.pan.2015.07.003] [Reference Citation Analysis]
|
| 6 |
Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol 2019;11:1758835919875568. [PMID: 31598142 DOI: 10.1177/1758835919875568] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 7 |
Maron R, Schechter B, Mancini M, Mahlknecht G, Yarden Y, Sela M. Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci USA. 2013;110:15389-15394. [PMID: 24003140 DOI: 10.1073/pnas.1313857110] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 8 |
Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 2009;13:339-62. [PMID: 19236156 DOI: 10.1517/14712590902735795] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 9 |
Johnson B, Vanderwalde A, Javadi N, Feldman R, Reddy SB. Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy. J Gastrointest Oncol 2016;7:E6-E12. [PMID: 27034805 DOI: 10.3978/j.issn.2078-6891.2015.091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 10 |
Hanoun N, Gayral M, Pointreau A, Buscail L, Cordelier P. Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. Hum Gene Ther. 2016;27:184-192. [PMID: 26731312 DOI: 10.1089/hum.2015.151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 11 |
Chang CF, Huang PW, Chen JS, Chen YY, Lu CH, Chang PH, Hung YS, Chou WC. Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Cancers (Basel) 2019;11:E57. [PMID: 30634387 DOI: 10.3390/cancers11010057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 12 |
Wu LW, Zhang JK, Rao M, Zhang ZY, Zhu HJ, Zhang C. Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment. Onco Targets Ther 2019;12:4585-93. [PMID: 31354292 DOI: 10.2147/OTT.S205097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 13 |
Tischer B, Bilang M, Kraemer M, Ronga P, Lacouture ME. A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies. Support Care Cancer 2018;26:1169-79. [PMID: 29116406 DOI: 10.1007/s00520-017-3938-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Cheng XB, Sato N, Kohi S, Koga A, Hirata K. 4-Methylumbelliferone inhibits enhanced hyaluronan synthesis and cell migration in pancreatic cancer cells in response to tumor-stromal interactions. Oncol Lett 2018;15:6297-301. [PMID: 29725394 DOI: 10.3892/ol.2018.8147] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina JH, Patel SG, Wu N, Hindoyan A, Farrell JJ, Li X, Dawson DW, Wu H. Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res 2012;18:1352-63. [PMID: 22261810 DOI: 10.1158/1078-0432.CCR-11-1539] [Cited by in Crossref: 131] [Cited by in F6Publishing: 93] [Article Influence: 13.1] [Reference Citation Analysis]
|
| 16 |
Jochims C, Mazitschek U, Jäger D, Goldschmidt H. [Targeted therapy in the treatment of solid tumors and in hematology-oncology. Advances and disappointments]. Internist (Berl) 2006;47:633-41. [PMID: 16767478 DOI: 10.1007/s00108-006-1626-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 17 |
Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol. 2010;7:493-507. [PMID: 20551942 DOI: 10.1038/nrclinonc.2010.97] [Cited by in Crossref: 448] [Cited by in F6Publishing: 414] [Article Influence: 37.3] [Reference Citation Analysis]
|
| 18 |
Conradt L, Godl K, Schaab C, Tebbe A, Eser S, Diersch S, Michalski CW, Kleeff J, Schnieke A, Schmid RM, Saur D, Schneider G. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. Neoplasia 2011;13:1026-34. [PMID: 22131878 DOI: 10.1593/neo.111016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 19 |
Guerra C, Barbacid M. Genetically engineered mouse models of pancreatic adenocarcinoma. Mol Oncol 2013;7:232-47. [PMID: 23506980 DOI: 10.1016/j.molonc.2013.02.002] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 20 |
Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG 2nd. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 2010;31:1135-43. [PMID: 20736812 DOI: 10.1097/MAO.0b013e3181eb328a] [Cited by in Crossref: 67] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 21 |
Wysocka O, Kulbacka J, Saczko J. Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. Prz Gastroenterol 2016;11:155-62. [PMID: 27713776 DOI: 10.5114/pg.2016.61438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 22 |
Rawat M, Kadian K, Gupta Y, Kumar A, Chain PSG, Kovbasnjuk O, Kumar S, Parasher G. MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential. Genes (Basel) 2019;10:E752. [PMID: 31557962 DOI: 10.3390/genes10100752] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 23 |
Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia 2012;14:690-701. [PMID: 22952422 DOI: 10.1593/neo.111810] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 24 |
Davis JL, Pandalai P, Ripley RT, Langan RC, Steinberg SM, Walker M, Toomey MA, Levy E, Avital I. Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial. Trials. 2011;12:129. [PMID: 21595953 DOI: 10.1186/1745-6215-12-129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 25 |
Tran HT, Zinner RG, Blumenschein GR Jr, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs 2011;29:499-505. [PMID: 20094773 DOI: 10.1007/s10637-009-9380-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Bruera G, Massacese S, Candria S, Galvano A, Manetta R, Giordano AV, Carducci S, Di Sibio A, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy. Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget 2018;9:31861-76. [PMID: 30159128 DOI: 10.18632/oncotarget.25870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 27 |
Baiocchi GL, Villanacci V, Rossi E, Zanotti D, Giulini SM. EGF-R Protein Expression and Gene Amplification do not Correlate in Pancreas Cancer. Gastroenterology Res 2008;1:55-6. [PMID: 27994708 DOI: 10.4021/gr2008.11.1248] [Reference Citation Analysis]
|
| 28 |
Suzuki N, Hazama S, Ueno T, Matsui H, Shindo Y, Iida M, Yoshimura K, Yoshino S, Takeda K, Oka M. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. J Immunother 2014;37:36-42. [PMID: 24316554 DOI: 10.1097/CJI.0000000000000012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 29 |
Riaz MK, Bal S, Wise-Draper T. The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer. J Surg Oncol 2016;114:323-8. [PMID: 27377825 DOI: 10.1002/jso.24333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 30 |
Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Mol Ther Oncolytics 2019;12:56-67. [PMID: 30705966 DOI: 10.1016/j.omto.2018.12.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 31 |
Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 32 |
Kong X, Li L, Li Z, Xie K. Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Cytokine Growth Factor Rev 2012;23:343-56. [PMID: 22749856 DOI: 10.1016/j.cytogfr.2012.06.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 33 |
Mohammed A, Janakiram NB, Pant S, Rao CV. Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel) 2015;7:1499-542. [PMID: 26266422 DOI: 10.3390/cancers7030850] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 34 |
Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol 2017;70:2536-51. [PMID: 29145954 DOI: 10.1016/j.jacc.2017.09.1096] [Cited by in Crossref: 145] [Cited by in F6Publishing: 123] [Article Influence: 29.0] [Reference Citation Analysis]
|
| 35 |
Tummers WS, Miller SE, Teraphongphom NT, Gomez A, Steinberg I, Huland DM, Hong S, Kothapalli SR, Hasan A, Ertsey R, Bonsing BA, Vahrmeijer AL, Swijnenburg RJ, Longacre TA, Fisher GA, Gambhir SS, Poultsides GA, Rosenthal EL. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Ann Surg Oncol 2018;25:1880-8. [PMID: 29667116 DOI: 10.1245/s10434-018-6453-2] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 36 |
Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C. Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing. Biomedicines 2020;8:E273. [PMID: 32764319 DOI: 10.3390/biomedicines8080273] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 37 |
Lonardo E, Hermann PC, Heeschen C. Pancreatic cancer stem cells - update and future perspectives. Mol Oncol. 2010;4:431-442. [PMID: 20580623 DOI: 10.1016/j.molonc.2010.06.002] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 38 |
Hakim N, Patel R, Devoe C, Saif MW. Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. Pancreas (Fairfax) 2019;3:e1-4. [PMID: 32030361 DOI: 10.17140/POJ-3-e010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 39 |
Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C. Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting. Cancer Manag Res 2017;9:141-8. [PMID: 28461766 DOI: 10.2147/CMAR.S126073] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 40 |
Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr Oncol Rep. 2013;15:182-189. [PMID: 23341367 DOI: 10.1007/s11912-012-0290-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 41 |
Felsenstein M, Hruban RH, Wood LD. New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. Adv Anat Pathol. 2018;25:131-142. [PMID: 28914620 DOI: 10.1097/pap.0000000000000172] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 42 |
Saung MT, Zheng L. Current Standards of Chemotherapy for Pancreatic Cancer. Clin Ther 2017;39:2125-34. [PMID: 28939405 DOI: 10.1016/j.clinthera.2017.08.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 43 |
van Tienhoven G, Gouma DJ, Richel DJ. Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma. Ther Adv Med Oncol 2011;3:27-33. [PMID: 21789153 DOI: 10.1177/1758834010383150] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 44 |
Cohen SJ, Zalupski MM, Modiano MR, Conkling P, Patt YZ, Davis P, Dorr RT, Boytim ML, Hersh EM. A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemother Pharmacol 2010;66:287-94. [PMID: 19855966 DOI: 10.1007/s00280-009-1162-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 45 |
Hsueh CT, Selim JH, Tsai JY, Hsueh CT. Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(31): 7080-7090 [PMID: 27610018 DOI: 10.3748/wjg.v22.i31.7080] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 46 |
Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci 2019;20:E4543. [PMID: 31540286 DOI: 10.3390/ijms20184543] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 47 |
Spratlin JL, Mackey JR. Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions. Cancers (Basel) 2010;2:2044-54. [PMID: 24281217 DOI: 10.3390/cancers2042044] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 48 |
Calvo F, Guillen Ponce C, Muñoz Beltran M, Sanjuanbenito Dehesa A. Multidisciplinary management of locally advanced–borderline resectable adenocarcinoma of the head of the pancreas. Clin Transl Oncol 2013;15:173-81. [DOI: 10.1007/s12094-012-0962-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 49 |
Mansoor H, Yusuf MA. Outcomes of endoscopic pyloric stenting in malignant gastric outlet obstruction: a retrospective study. BMC Res Notes 2013;6:280. [PMID: 23870091 DOI: 10.1186/1756-0500-6-280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 50 |
Li Q, Yan H, Liu W, Zhen H, Yang Y, Cao B. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials. PLoS One 2014;9:e104346. [PMID: 25093849 DOI: 10.1371/journal.pone.0104346] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 51 |
Cui Y, Chang D, Liu M, Lin C, Zhao B, Zhang X, Gong M. Identification of exon 19 and 21 mutations of EGFR gene in Chinese patients with esophageal squamous cell carcinoma. World J Surg Oncol 2013;11:266. [PMID: 24103528 DOI: 10.1186/1477-7819-11-266] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 52 |
Francis T, Graf A, Hodges K, Kennedy L, Hargrove L, Price M, Kearney K, Francis H. Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings. Hepatobiliary Surg Nutr 2013;2:216-26. [PMID: 24570946 DOI: 10.3978/j.issn.2304-3881.2013.08.06] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
|
| 53 |
Fernandes GDS, Pereira A. Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? ESMO Open 2019;4:e000537. [PMID: 31354965 DOI: 10.1136/esmoopen-2019-000537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 54 |
Fenocchio E, Filippi R, Lombardi P, Quarà V, Milanesio M, Aimar G, Leone F, Aglietta M. Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? Cancers (Basel) 2019;11:E1547. [PMID: 31614884 DOI: 10.3390/cancers11101547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 55 |
Scheithauer W, Putora PM, Grünberger B, Eisterer W, Wöll E, Prager G, Schaberl-Moser R, Greil R, Glatzer M. Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. Therap Adv Gastroenterol 2019;12:1756284819877635. [PMID: 31579123 DOI: 10.1177/1756284819877635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 56 |
Dakik HK, Moskovic DJ, Carlson PJ, Tamm EP, Qiao W, Wolff RA, Abbruzzese JL, Fogelman DR. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2012;69:425-430. [PMID: 21850466 DOI: 10.1007/s00280-011-1705-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 57 |
Narayanan V, Weekes CD. Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol 2016; 8(4): 366-379 [PMID: 27096032 DOI: 10.4251/wjgo.v8.i4.366] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 58 |
Cengel KA, Voong KR, Chandrasekaran S, Maggiorella L, Brunner TB, Stanbridge E, Kao GD, McKenna WG, Bernhard EJ. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 2007;9:341-8. [PMID: 17460778 DOI: 10.1593/neo.06823] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 59 |
Orlandi A, Calegari MA, Martini M, Cocomazzi A, Bagalà C, Indellicati G, Zurlo V, Basso M, Cassano A, Larocca LM, Barone C. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. Clin Transl Oncol 2016;18:988-95. [PMID: 26742940 DOI: 10.1007/s12094-015-1471-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 60 |
Shimasaki T, Kitano A, Motoo Y, Minamoto T. Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. J Carcinog 2012;11:15. [PMID: 23230392 DOI: 10.4103/1477-3163.100866] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 61 |
Kordbacheh F, Farah CS. Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5471. [PMID: 34771633 DOI: 10.3390/cancers13215471] [Reference Citation Analysis]
|
| 62 |
Wen CL, Huang K, Jiang LL, Lu XX, Dai YT, Shi MM, Tang XM, Wang QB, Zhang XD, Wang PH, Li HT, Ruan XX, Wang LW, Wang XJ, Wang Q, Lu W, Xiang XQ, Sun X, Xu YH, Lai LH, Zhan Q, Li HW, Peng CH, Chen J, Huang JY, Ye DY, Chen SJ, Chen Z, Li M, Fang Y, Shen BY, Zhou L. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 2019;116:23264-73. [PMID: 31662475 DOI: 10.1073/pnas.1914557116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 63 |
Park SJ, Kim SM, Moon JH, Kim JH, Shin JS, Hong SW, Shin YJ, Lee DH, Lee EY, Hwang IY, Kim JE, Kim KP, Hong YS, Lee WK, Choi EK, Lee JS, Jin DH, Kim TW. SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin. Tumour Biol 2016;37:4323-30. [PMID: 26493999 DOI: 10.1007/s13277-015-4216-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 64 |
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 65 |
Chen K, Qian W, Li J, Jiang Z, Cheng L, Yan B, Cao J, Sun L, Zhou C, Lei M, Duan W, Ma J, Ma Q, Ma Z. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Mol Oncol 2017;11:1475-92. [PMID: 28783244 DOI: 10.1002/1878-0261.12116] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 66 |
Fan X, Zhang X, Shen J, Zhao H, Yu X, Chen Y, Zhuang Z, Deng X, Feng H, Wang Y, Peng L. Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis. PLoS One 2016;11:e0149028. [PMID: 26871953 DOI: 10.1371/journal.pone.0149028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 67 |
Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, Varlet P, Aerts I, Riccardi R, Jaspan T, Chatelut E, Le Deley MC, Paoletti X, Saint-Rose C, Leblond P, Morland B, Gentet JC, Méresse V, Vassal G; ITCC (Innovative Therapies for Children with Cancer) European Consortium. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol 2011;13:109-18. [PMID: 20974795 DOI: 10.1093/neuonc/noq141] [Cited by in Crossref: 107] [Cited by in F6Publishing: 94] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 68 |
Ahmed S, Shahid RK, Gesy K. Cancer care burden: aiming at the Achilles heel. Curr Oncol 2015;22:e134-8. [PMID: 26089722 DOI: 10.3747/co.22.2252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 69 |
Wang YN, Lee HH, Hung MC. A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases. J Biomed Sci 2018;25:83. [PMID: 30449278 DOI: 10.1186/s12929-018-0484-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 70 |
Vena F, Bayle S, Nieto A, Quereda V, Aceti M, Frydman SM, Sansil SS, Grant W, Monastyrskyi A, McDonald P, Roush WR, Teng M, Duckett D. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase. Mol Cancer Ther. 2020;19:1623-1635. [PMID: 32430484 DOI: 10.1158/1535-7163.mct-19-0997] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 71 |
Sharif S, Ramanathan RK, Potter D, Cieply K, Krasinskas AM. HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. Dig Dis Sci 2008;53:3026-32. [PMID: 18463983 DOI: 10.1007/s10620-008-0267-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 72 |
Zukas AM, Schiff D. Neurological complications of new chemotherapy agents. Neuro Oncol 2018;20:24-36. [PMID: 28992326 DOI: 10.1093/neuonc/nox115] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 73 |
Miyahara K, Nouso K, Yamamoto K. Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J Gastroenterol 2014; 20(15): 4151-4159 [PMID: 24764653 DOI: 10.3748/wjg.v20.i15.4151] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 74 |
Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB 3rd. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29:4105-4112. [PMID: 21969502 DOI: 10.1200/jco.2011.34.8904] [Cited by in Crossref: 517] [Cited by in F6Publishing: 235] [Article Influence: 47.0] [Reference Citation Analysis]
|
| 75 |
Haas M, Heinemann V, Kullmann F, Laubender RP, Klose C, Bruns CJ, Holdenrieder S, Modest DP, Schulz C, Boeck S. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139:681-689. [PMID: 23315099 DOI: 10.1007/s00432-012-1371-3] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 9.9] [Reference Citation Analysis]
|
| 76 |
Elsner A, Lange F, Fitzner B, Heuschkel M, Krause BJ, Jaster R. Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells. World J Gastroenterol 2014; 20(24): 7914-7925 [PMID: 24976727 DOI: 10.3748/wjg.v20.i24.7914] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 77 |
Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.3322/caac.21190] [Cited by in Crossref: 479] [Cited by in F6Publishing: 473] [Article Influence: 53.2] [Reference Citation Analysis]
|
| 78 |
Vergoulidou M. More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. Biomark Insights 2015;10:33-40. [PMID: 26483606 DOI: 10.4137/BMI.S22436] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 79 |
Uwagawa T, Yanaga K. Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. Surg Today 2015;45:1481-8. [PMID: 25673034 DOI: 10.1007/s00595-015-1129-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 80 |
Wilkowski R, Boeck S, Ostermaier S, Sauer R, Herbst M, Fietkau R, Flentje M, Miethe S, Boettcher HD, Scholten T, Bruns CJ, Rau HG, Hinke A, Heinemann V. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study. Br J Cancer 2009;101:1853-9. [PMID: 19904268 DOI: 10.1038/sj.bjc.6605420] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 81 |
Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK. A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomedicine (Taipei). 2017;7:23. [PMID: 29130448 DOI: 10.1051/bmdcn/2017070423] [Cited by in Crossref: 150] [Cited by in F6Publishing: 131] [Article Influence: 30.0] [Reference Citation Analysis]
|
| 82 |
Wang Y, Lakoma A, Zogopoulos G. Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Genes (Basel) 2020;11:E1098. [PMID: 32967105 DOI: 10.3390/genes11091098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 83 |
LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs. 2013;31:943-948. [PMID: 23263993 DOI: 10.1007/s10637-012-9916-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 84 |
Desai AM, Lichtman SM. Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biol Med. 2015;12:284-291. [PMID: 26779365 DOI: 10.7497/j.issn.2095-3941.2015.0078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 85 |
Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM, George TJ Jr. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med 2015;4:1224-39. [PMID: 25766842 DOI: 10.1002/cam4.444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 86 |
Ji JS, Han CW, Jang JW, Lee BI, Kim BW, Choi H, Kim JY, Kang YN, Kay CS, Choi IB. Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer. Radiat Oncol 2010;5:60. [PMID: 20584299 DOI: 10.1186/1748-717X-5-60] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 87 |
Koutsounas I, Giaginis C, Patsouris E, Theocharis S. Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J Gastroenterol 2013; 19(6): 813-828 [PMID: 23430136 DOI: 10.3748/wjg.v19.i6.813] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 88 |
Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol 2016;13:750-65. [PMID: 27531700 DOI: 10.1038/nrclinonc.2016.119] [Cited by in Crossref: 115] [Cited by in F6Publishing: 113] [Article Influence: 19.2] [Reference Citation Analysis]
|
| 89 |
Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012;17:192-200. [PMID: 22250057 DOI: 10.1634/theoncologist.2011-0268] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 90 |
Gibbs P, Do C, Lipton L, Cade DN, Tapner MJ, Price D, Bower GD, Dowling R, Lichtenstein M, van Hazel GA. Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma. BMC Cancer 2015;15:802. [PMID: 26503593 DOI: 10.1186/s12885-015-1822-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 91 |
El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs 2011;29:694-9. [PMID: 20107864 DOI: 10.1007/s10637-010-9386-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 92 |
van Mackelenbergh MG, Stroes CI, Spijker R, van Eijck CHJ, Wilmink JW, Bijlsma MF, van Laarhoven HWM. Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 31035512 DOI: 10.3390/cancers11050588] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 93 |
Ansari D, Chen BC, Dong L, Zhou MT, Andersson R. Pancreatic cancer: Translational research aspects and clinical implications. World J Gastroenterol 2012; 18(13): 1417-1424 [PMID: 22509073 DOI: 10.3748/wjg.v18.i13.1417] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 94 |
Oyasiji T, Ma WW. Novel adjuvant therapies for pancreatic adenocarcinoma. J Gastrointest Oncol 2015;6:430-5. [PMID: 26261729 DOI: 10.3978/j.issn.2078-6891.2015.031] [Reference Citation Analysis]
|
| 95 |
Ota K, Harada T, Otsubo K, Fujii A, Tsuchiya Y, Tanaka K, Okamoto I, Nakanishi Y. Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay. Oncotarget 2017;8:72127-32. [PMID: 29069773 DOI: 10.18632/oncotarget.19552] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 96 |
Kudgus RA, Szabolcs A, Khan JA, Walden CA, Reid JM, Robertson JD, Bhattacharya R, Mukherjee P. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. PLoS One 2013;8:e57522. [PMID: 23483913 DOI: 10.1371/journal.pone.0057522] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 97 |
Halfdanarson TR, Haraldsdottir S, Borad MJ. Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Res 2013;2:105. [PMID: 24327864 DOI: 10.12688/f1000research.2-105.v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 98 |
Hagiwara Y, Ohashi Y, Okusaka T, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Cheng AL, Kihara K, Sato A, Tanaka M. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open 2017;2:e000151. [PMID: 28761731 DOI: 10.1136/esmoopen-2016-000151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 99 |
Shimasaki T, Ishigaki Y, Nakamura Y, Takata T, Nakaya N, Nakajima H, Sato I, Zhao X, Kitano A, Kawakami K, Tanaka T, Takegami T, Tomosugi N, Minamoto T, Motoo Y. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine. J Gastroenterol 2012;47:321-33. [PMID: 22041920 DOI: 10.1007/s00535-011-0484-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 100 |
Hang J, Xue P, Yang H, Li S, Chen D, Zhu L, Huang W, Ren S, Zhu Y, Wang L. Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Sci Rep 2017;7:2993. [PMID: 28592881 DOI: 10.1038/s41598-017-03153-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 101 |
Hojjat-Farsangi M. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int J Mol Sci 2014;15:13768-801. [PMID: 25110867 DOI: 10.3390/ijms150813768] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 15.1] [Reference Citation Analysis]
|
| 102 |
Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg 2013;257:17-26. [PMID: 22895395 DOI: 10.1097/SLA.0b013e31825ffbfb] [Cited by in Crossref: 120] [Cited by in F6Publishing: 64] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 103 |
Eng JW, Mace TA, Sharma R, Twum DYF, Peng P, Gibbs JF, Pitoniak R, Reed CB, Abrams SI, Repasky EA, Hylander BL. Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. J Immunother Cancer 2016;4:33. [PMID: 27330806 DOI: 10.1186/s40425-016-0136-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 104 |
Parkin A, Man J, Timpson P, Pajic M. Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. FEBS J 2019;286:3510-39. [PMID: 31330086 DOI: 10.1111/febs.15011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 105 |
Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82. [PMID: 18373843 DOI: 10.1186/11471-2407-8-82] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 106 |
Gulec SA, Cohen SJ, Pennington KL, Zuckier LS, Hauke RJ, Horne H, Wegener WA, Teoh N, Gold DV, Sharkey RM, Goldenberg DM. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial. Clin Cancer Res 2011;17:4091-100. [PMID: 21527562 DOI: 10.1158/1078-0432.CCR-10-2579] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 107 |
Chan E, Mulkerin D, Rothenberg M, Holen KD, Lockhart AC, Thomas J, Berlin J. A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Invest New Drugs. 2008;26:241-247. [PMID: 18217204 DOI: 10.1007/s10637-008-9118-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 108 |
Sasahara Y, Narimatsu H, Fukao A, Yoshioka T. Approving molecularly targeted drugs: different approval processes for cytotoxic agents. Int J Clin Oncol 2016;21:1004-13. [PMID: 27105626 DOI: 10.1007/s10147-016-0980-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 109 |
Olson P, Chu GC, Perry SR, Nolan-Stevaux O, Hanahan D. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci USA. 2011;108:E1275-E1284. [PMID: 22084065 DOI: 10.1073/pnas.1111079108] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 110 |
Türeci Ӧ, Mitnacht-Kraus R, Wöll S, Yamada T, Sahin U. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology 2019;8:e1523096. [PMID: 30546962 DOI: 10.1080/2162402X.2018.1523096] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 111 |
Didolkar MS, Coleman CW, Brenner MJ, Chu KU, Olexa N, Stanwyck E, Yu A, Neerchal N, Rabinowitz S. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg. 2010;14:1547-1559. [PMID: 20839073 DOI: 10.1007/s11605-010-1323-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 112 |
Ohuchida K, Mizumoto K, Kayashima T, Fujita H, Moriyama T, Ohtsuka T, Ueda J, Nagai E, Hashizume M, Tanaka M. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol 2011;18:2381-7. [PMID: 21347785 DOI: 10.1245/s10434-011-1602-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 113 |
Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, Schrag D; Cancer and Leukemia Group B. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 2012;43:205-17. [PMID: 22104618 DOI: 10.1016/j.jpainsymman.2011.09.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 114 |
Mao YH, Yu CZ. Current situation and predicament of multidisciplinary treatment of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2015; 23(36): 5750-5759 [DOI: 10.11569/wcjd.v23.i36.5750] [Reference Citation Analysis]
|
| 115 |
Chen J, Chen L, Yu J, Xu Y, Wang X, Zeng Z, Liu N, Xu F, Yang S. Meta‑analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment‑associated toxicities. Mol Med Rep 2019;19:477-89. [PMID: 30431091 DOI: 10.3892/mmr.2018.9638] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 116 |
Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res 2009;15:6639-48. [PMID: 19825949 DOI: 10.1158/1078-0432.CCR-09-0951] [Cited by in Crossref: 80] [Cited by in F6Publishing: 60] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 117 |
Gergely PA, Murnyák B, Bencze J, Kurucz A, Varjas T, Gombos K, Hortobágyi T. Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice. Biomed Res Int 2019;2019:8670398. [PMID: 30882001 DOI: 10.1155/2019/8670398] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 118 |
Li J, Wientjes MG, Au JL. Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J 2010;12:223-32. [PMID: 20198462 DOI: 10.1208/s12248-010-9181-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 119 |
Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, Yang J, Wolpin B. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Invest New Drugs 2016;34:319-28. [PMID: 26994014 DOI: 10.1007/s10637-016-0343-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 120 |
Kanji ZS, Gallinger S. Diagnosis and management of pancreatic cancer. CMAJ. 2013;185:1219-1226. [PMID: 23610017 DOI: 10.1503/cmaj.121368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 121 |
Tsai CS, Park JW, Chen LT. Nanovector-based therapies in advanced pancreatic cancer. J Gastrointest Oncol 2011;2:185-94. [PMID: 22811849 DOI: 10.3978/j.issn.2078-6891.2011.034] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
|
| 122 |
Banerjee S, Choi M, Aboukameel A, Wang Z, Mohammad M, Chen J, Yang D, Sarkar FH, Mohammad RM. Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells. Pancreas 2010;39:323-31. [PMID: 19823097 DOI: 10.1097/MPA.0b013e3181bb95e7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 123 |
Husain K, Centeno BA, Chen DT, Hingorani SR, Sebti SM, Malafa MP. Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer. Cancer Prev Res (Phila) 2013;6:1074-83. [PMID: 23963802 DOI: 10.1158/1940-6207.CAPR-13-0157] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 124 |
Wishart G, Gupta P, Schettino G, Nisbet A, Velliou E. 3d tissue models as tools for radiotherapy screening for pancreatic cancer. Br J Radiol 2021;94:20201397. [PMID: 33684308 DOI: 10.1259/bjr.20201397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 125 |
Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 2007;56:1134-1152. [PMID: 17625148 DOI: 10.1136/gut.2006.103333] [Cited by in Crossref: 84] [Cited by in F6Publishing: 179] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 126 |
Khan K, Cunningham D, Peckitt C, Barton S, Tait D, Hawkins M, Watkins D, Starling N, Rao S, Begum R, Thomas J, Oates J, Guzzardo V, Fassan M, Braconi C, Chau I. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget 2016;7:12672-81. [PMID: 26862857 DOI: 10.18632/oncotarget.7208] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 127 |
KalantarMotamedi Y, Choi RJ, Koh SB, Bramhall JL, Fan TP, Bender A. Prediction and identification of synergistic compound combinations against pancreatic cancer cells. iScience 2021;24:103080. [PMID: 34585118 DOI: 10.1016/j.isci.2021.103080] [Reference Citation Analysis]
|
| 128 |
Liu S, Qin Z, Xu J, Zeng J, Chen J, Niu L, Xu M. Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study. Onco Targets Ther. 2019;12:1341-1350. [PMID: 30863100 DOI: 10.2147/ott.s186721] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 129 |
Zhu SK, Xu T, Wang R. Prospects and challenges of immunotherapy for pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2019; 27(1): 6-12 [DOI: 10.11569/wcjd.v27.i1.6] [Reference Citation Analysis]
|
| 130 |
Sloss CM, Wang F, Palladino MA, Cusack JC Jr. Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells. Oncogene 2010;29:3146-52. [PMID: 20208558 DOI: 10.1038/onc.2010.52] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 131 |
Huang P, Zhong XY, Xu Y, Cui YF. Role of neoadjuvant therapy and adjuvant therapy in treatment of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(14): 1292-1296 [DOI: 10.11569/wcjd.v21.i14.1292] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 132 |
Hirsh V. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol 2011;18:126-38. [PMID: 21655159 DOI: 10.3747/co.v18i3.877] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 133 |
Debnath B, Xu S, Grande F, Garofalo A, Neamati N. Small molecule inhibitors of CXCR4. Theranostics. 2013;3:47-75. [PMID: 23382786 DOI: 10.7150/thno.5376] [Cited by in Crossref: 173] [Cited by in F6Publishing: 166] [Article Influence: 19.2] [Reference Citation Analysis]
|
| 134 |
Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res. 2008;14:5142-5149. [PMID: 18698032 DOI: 10.1158/1078-0432.ccr-07-4072] [Cited by in Crossref: 87] [Cited by in F6Publishing: 69] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 135 |
Chan SL, Chan ST, Chan EH, He ZX. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin J Cancer 2014;33:267-76. [PMID: 24472302 DOI: 10.5732/cjc.013.10134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 136 |
Xia T, Jiang H, Li C, Tian M, Zhang H. Molecular imaging in tracking tumor stem-like cells. J Biomed Biotechnol 2012;2012:420364. [PMID: 22570529 DOI: 10.1155/2012/420364] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 137 |
Harano Y, Babazono A, Fujita T, Jiang P. Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort study. Journal of Geriatric Oncology 2019;10:420-6. [DOI: 10.1016/j.jgo.2018.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 138 |
Ren H, Mai G, Liu Y, Xiang R, Yang C, Su W. Eukaryotic Translation Initiation Factor 3 Subunit B Is a Promoter in the Development and Progression of Pancreatic Cancer. Front Oncol 2021;11:644156. [PMID: 33996561 DOI: 10.3389/fonc.2021.644156] [Reference Citation Analysis]
|
| 139 |
Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O’Dwyer P, Haller D, Catalano P. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778-3785. [PMID: 19581537 DOI: 10.1200/jco.2008.20.9007] [Cited by in Crossref: 285] [Cited by in F6Publishing: 150] [Article Influence: 21.9] [Reference Citation Analysis]
|
| 140 |
Riess H, Pelzer U, Hilbig A, Stieler J, Opitz B, Scholten T, Kauschat-Brüning D, Bramlage P, Dörken B, Oettle H. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer 2008;8:361. [PMID: 19055847 DOI: 10.1186/1471-2407-8-361] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 141 |
Rasheed ZA, Kowalski J, Smith BD, Matsui W. Concise review: Emerging concepts in clinical targeting of cancer stem cells. Stem Cells. 2011;29:883-887. [PMID: 21509907 DOI: 10.1002/stem.648] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 142 |
Dogra P, Ramírez JR, Peláez MJ, Wang Z, Cristini V, Parasher G, Rawat M. Mathematical Modeling to Address Challenges in Pancreatic Cancer. Curr Top Med Chem 2020;20:367-76. [PMID: 31893993 DOI: 10.2174/1568026620666200101095641] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 143 |
Matsuoka T, Yashiro M. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. World J Gastroenterol 2016; 22(2): 776-789 [PMID: 26811624 DOI: 10.3748/wjg.v22.i2.776] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 144 |
Sorber R, Teper Y, Abisoye-Ogunniyan A, Waterfall JJ, Davis S, Killian JK, Pineda M, Ray S, McCord MR, Pflicke H, Burkett SS, Meltzer PS, Rudloff U. Whole Genome Sequencing of Newly Established Pancreatic Cancer Lines Identifies Novel Somatic Mutation (c.2587G>A) in Axon Guidance Receptor Plexin A1 as Enhancer of Proliferation and Invasion. PLoS One 2016;11:e0149833. [PMID: 26962861 DOI: 10.1371/journal.pone.0149833] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 145 |
Pimienta M, Edderkaoui M, Wang R, Pandol S. The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. Front Physiol 2017;8:381. [PMID: 28626429 DOI: 10.3389/fphys.2017.00381] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 146 |
Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 672] [Article Influence: 75.6] [Reference Citation Analysis]
|
| 147 |
Spano JP, Moore MJ, Pithavala YK, Ricart AD, Kim S, Rixe O. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs 2012;30:1531-9. [PMID: 21670972 DOI: 10.1007/s10637-011-9697-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 148 |
Kim HW, Lee JC, Paik KH, Lee YS, Hwang JH, Kim J. Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma. Medicine (Baltimore) 2015;94:e1012. [PMID: 26107667 DOI: 10.1097/MD.0000000000001012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 149 |
Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, Marubashi S, Takemasa I, Nagano H, Dono K, Nakamori S, Monden M, Mori M, Doki Y, Bepler G. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene. 2009;28:2903-2909. [PMID: 19543324 DOI: 10.1038/onc.2009.158] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 150 |
Pines G, Köstler WJ, Yarden Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett 2010;584:2699-706. [PMID: 20388509 DOI: 10.1016/j.febslet.2010.04.019] [Cited by in Crossref: 104] [Cited by in F6Publishing: 91] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 151 |
Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 2016;22:278-87. [PMID: 26855150 DOI: 10.1038/nm.4038] [Cited by in Crossref: 127] [Cited by in F6Publishing: 105] [Article Influence: 21.2] [Reference Citation Analysis]
|
| 152 |
Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ, Vickers SM. Molecular targeted therapies for pancreatic cancer. Am J Surg 2008;196:430-41. [PMID: 18718222 DOI: 10.1016/j.amjsurg.2008.04.009] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 153 |
Kipps E, Young K, Starling N. Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. Ther Adv Med Oncol 2017;9:159-70. [PMID: 28344661 DOI: 10.1177/1758834016688816] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 154 |
Chiramel J, Backen AC, Pihlak R, Lamarca A, Frizziero M, Tariq NU, Hubner RA, Valle JW, Amir E, McNamara MG. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci 2017;18:E909. [PMID: 28445400 DOI: 10.3390/ijms18050909] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 155 |
Ouaïssi M, Giger U, Sielezneff I, Pirrò N, Sastre B, Ouaissi A. Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. J Biomed Biotechnol 2011;2011:315939. [PMID: 20981265 DOI: 10.1155/2011/315939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 156 |
Jiang Y, Zeng Z, Zeng J, Liu C, Qiu J, Li Y, Tang J, Mo N, Du L, Ma J. Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:736113. [PMID: 34650920 DOI: 10.3389/fonc.2021.736113] [Reference Citation Analysis]
|
| 157 |
Li Y, Xie P, Lu L, Wang J, Diao L, Liu Z, Guo F, He Y, Liu Y, Huang Q, Liang H, Li D, He F. An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network. Nat Commun 2017;8:347. [PMID: 28839186 DOI: 10.1038/s41467-017-00299-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 158 |
Lonardo E, Cioffi M, Sancho P, Crusz S, Heeschen C. Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies. J Vis Exp 2015;:e52801. [PMID: 26132091 DOI: 10.3791/52801] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 159 |
Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol 2016;39:340-5. [PMID: 24685886 DOI: 10.1097/COC.0000000000000068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 160 |
Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019;68:742-58. [PMID: 30396902 DOI: 10.1136/gutjnl-2018-316822] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 161 |
Khan MA, Srivastava SK, Bhardwaj A, Singh S, Arora S, Zubair H, Carter JE, Singh AP. Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications. Oncotarget 2015;6:39140-50. [PMID: 25970774 DOI: 10.18632/oncotarget.3784] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 162 |
Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 163 |
Sato S, Nakamura T, Katagiri T, Tsuchikawa T, Kushibiki T, Hontani K, Takahashi M, Inoko K, Takano H, Abe H, Takeuchi S, Ono M, Kuwabara S, Umemoto K, Suzuki T, Sato O, Nakamura Y, Hirano S. Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. Oncotarget 2017;8:113662-72. [PMID: 29371937 DOI: 10.18632/oncotarget.21939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 164 |
Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefèvre L, Bonnetain F, Lévy P, Raymond E, Ruszniewski P, Louvet C, Hammel P. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol 2012; 18(33): 4533-4541 [PMID: 22969226 DOI: 10.3748/wjg.v18.i33.4533] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 165 |
Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol. 2017;8:566-571. [PMID: 28736643 DOI: 10.21037/jgo.2017.02.02] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 166 |
Wong HH, Lemoine NR. Novel therapies for pancreatic cancer: setbacks and progress. Future Oncol 2010;6:1061-4. [PMID: 20624116 DOI: 10.2217/fon.10.70] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 167 |
Horibe Y, Adachi S, Yasuda I, Yamauchi T, Kawaguchi J, Kozawa O, Shimizu M, Moriwaki H. Anticancer effect of arsenite on cell migration, cell cycle and apoptosis in human pancreatic cancer cells. Oncol Lett 2016;12:177-82. [PMID: 27347121 DOI: 10.3892/ol.2016.4564] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 168 |
Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007;254:165-77. [PMID: 17367921 DOI: 10.1016/j.canlet.2007.02.006] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 169 |
Martín AJ, Alfonso PG, Rupérez AB, Jiménez MM. Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2. Oncol Lett 2016;12:727-30. [PMID: 27347207 DOI: 10.3892/ol.2016.4667] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 170 |
Hao J, Yang X, Ding XL, Guo LM, Zhu CH, Ji W, Zhou T, Wu XZ. Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation. Sci Rep 2016;6:32809. [PMID: 27609096 DOI: 10.1038/srep32809] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 171 |
Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622. [PMID: 20606091 DOI: 10.1200/jco.2010.28.1386] [Cited by in Crossref: 562] [Cited by in F6Publishing: 331] [Article Influence: 46.8] [Reference Citation Analysis]
|
| 172 |
Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res. 2008;14:8143-8151. [PMID: 19088029 DOI: 10.1158/1078-0432.ccr-08-1539] [Cited by in Crossref: 94] [Cited by in F6Publishing: 58] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 173 |
Delitto D, Black BS, Sorenson HL, Knowlton AE, Thomas RM, Sarosi GA, Moldawer LL, Behrns KE, Liu C, George TJ. The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. BMC Cancer. 2015;15:783. [PMID: 26498838 DOI: 10.1186/s12885-015-1820-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 174 |
Sahin IH, Geyer AI, Kelly DW, O'Reilly EM. Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications. Clin Colorectal Cancer 2016;15:24-31. [PMID: 26395520 DOI: 10.1016/j.clcc.2015.08.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 175 |
Ranganathan P, Pramesh CS, Buyse M. Common pitfalls in statistical analysis: Clinical versus statistical significance. Perspect Clin Res 2015;6:169-70. [PMID: 26229754 DOI: 10.4103/2229-3485.159943] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 176 |
Gong J, Muñoz AR, Pingali S, Payton-Stewart F, Chan DE, Freeman JW, Ghosh R, Kumar AP. Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells. Mol Carcinog 2017;56:402-11. [PMID: 27208550 DOI: 10.1002/mc.22503] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 177 |
Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol 2013; 19(28): 4511-4519 [PMID: 23901226 DOI: 10.3748/wjg.v19.i28.4511] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 178 |
Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 179 |
Okamoto Y, Maeba T, Kakinoki K, Okano K, Izuishi K, Wakabayashi H, Usuki H, Suzuki Y. A patient with unresectable advanced pancreatic cancer achieving long-term survival with gemcitabine chemotherapy. World J Gastroenterol. 2008;14:6876-6880. [PMID: 19058319 DOI: 10.3748/wjg.14.6876] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 180 |
Ormanns S, Siveke JT, Heinemann V, Haas M, Sipos B, Schlitter AM, Esposito I, Jung A, Laubender RP, Kruger S, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Geissler M, Greten TF, Kirchner T, Boeck S. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer 2014;14:624. [PMID: 25164437 DOI: 10.1186/1471-2407-14-624] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 181 |
Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, Shin DB. Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy. Cancer Res Treat 2016;48:1264-73. [PMID: 27034148 DOI: 10.4143/crt.2015.250] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 182 |
Tang Y, Liu F, Zheng C, Sun S, Jiang Y. Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation. J Exp Clin Cancer Res 2012;31:73. [PMID: 22967941 DOI: 10.1186/1756-9966-31-73] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 183 |
Callegaro-Filho D, Kavanagh JJ, Nick AM, Ramirez PT, Schmeler KM. Sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases. Case Rep Oncol 2014;7:97-101. [PMID: 24575024 DOI: 10.1159/000358916] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 184 |
Burris H, Stephenson J, Otterson GA, Stein M, McGreivy J, Sun YN, Ingram M, Ye Y, Schwartzberg LS. Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer. J Oncol 2011;2011:853931. [PMID: 21559248 DOI: 10.1155/2011/853931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 185 |
Babiker HM, Karass M, Recio-Boiles A, Chandana SR, McBride A, Mahadevan D. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Expert Opin Investig Drugs 2019;28:583-92. [PMID: 31215251 DOI: 10.1080/13543784.2019.1632289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 186 |
Knoop RF, Sparn M, Waldmann J, Plassmeier L, Bartsch DK, Lauth M, Hudemann C, Fendrich V. Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer. Neoplasia 2014;16:463-70. [PMID: 24953430 DOI: 10.1016/j.neo.2014.05.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 187 |
Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 188 |
Polireddy K, Chen Q. Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. J Cancer 2016;7:1497-514. [PMID: 27471566 DOI: 10.7150/jca.14922] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 189 |
Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019;12:130. [PMID: 31801585 DOI: 10.1186/s13045-019-0824-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 190 |
Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008;3:1003-1011. [PMID: 18758303 DOI: 10.1097/jto.0b013e31818396a4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 191 |
Cui J, Yang H, Liu J, Chen D, Hu J, Zhang H, Wang Y, Han T, Mao T, Jiao F, Biskup E, Pan Y, Liu M, Wang L. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer 2021;21:672. [PMID: 34098895 DOI: 10.1186/s12885-021-08375-6] [Reference Citation Analysis]
|
| 192 |
Perez R, Moreno E, Garrido G, Crombet T. EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. Cancers (Basel) 2011;3:2014-31. [PMID: 24212794 DOI: 10.3390/cancers3022014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 193 |
Maier-Stocker C, Bitzer M, Malek NP, Plentz RR. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort. Scand J Gastroenterol 2014;49:1480-5. [PMID: 25390691 DOI: 10.3109/00365521.2014.978816] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 194 |
Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q, Li M. Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets. 2011;15:817-828. [PMID: 21391891 DOI: 10.1517/14728222.2011.566216] [Cited by in Crossref: 132] [Cited by in F6Publishing: 133] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 195 |
Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E, Walde D, Goel R, Southwood B, Gauthier I, Walsh W, McIntosh L, Seymour L. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Invest New Drugs 2012;30:779-86. [PMID: 21170669 DOI: 10.1007/s10637-010-9611-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 196 |
Martin LK, Bekaii-Saab T. Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants? Thrombosis. 2012;2012:758385. [PMID: 23024860 DOI: 10.1155/2012/758385] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 197 |
Dong PP, Fang ZZ, Zhang YY, Ge GB, Mao YX, Zhu LL, Qu YQ, Li W, Wang LM, Liu CX, Yang L. Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib. Acta Pharmacol Sin 2011;32:399-407. [PMID: 21372830 DOI: 10.1038/aps.2010.218] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 198 |
Jain R, Vijayvergia N, Devarajan K, Lewis B, Denlinger CS, Cohen SJ, Dotan E. Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era. J Geriatr Oncol 2020;11:640-6. [PMID: 31917116 DOI: 10.1016/j.jgo.2019.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 199 |
Moravec R, Divi R, Verma M. Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World J Gastrointest Oncol 2017; 9(6): 235-250 [PMID: 28656074 DOI: 10.4251/wjgo.v9.i6.235] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 200 |
Elebro J, Heby M, Warfvinge CF, Nodin B, Eberhard J, Jirström K. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. PLoS One 2016;11:e0153533. [PMID: 27070783 DOI: 10.1371/journal.pone.0153533] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 201 |
Thomas NA, Abraham RG, Dedi B, Krucher NA. Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells. Int J Oncol 2019;54:527-36. [PMID: 30535494 DOI: 10.3892/ijo.2018.4658] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
|
| 202 |
Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, von Weikersthal LF, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, Höhler T, Ko YD, Jung A, Neugebauer S, Boeck S. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013;62:751-9. [PMID: 22773551 DOI: 10.1136/gutjnl-2012-302759] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 203 |
Delpu Y, Hanoun N, Lulka H, Sicard F, Selves J, Buscail L, Torrisani J, Cordelier P. Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics. 2011;12:15-24. [PMID: 21886451 DOI: 10.2174/138920211794520132] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 204 |
Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol 2017;8:387-404. [PMID: 28736627 DOI: 10.21037/jgo.2017.01.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 205 |
Meng Z, Garrett CR, Shen Y, Liu L, Yang P, Huo Y, Zhao Q, Spelman AR, Ng CS, Chang DZ. Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. Br J Cancer. 2012;107:411-416. [PMID: 22782343 DOI: 10.1038/bjc.2012.283] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 206 |
Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 2010;12:1061-70. [PMID: 20615922 DOI: 10.1093/neuonc/noq072] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 207 |
Spratlin JL, Chu Q, Koski S, King K, Mulder K. Targeting metastatic upper gastrointestinal adenocarcinomas. World J Clin Oncol 2011; 2(3): 135-149 [PMID: 21611088 DOI: 10.5306/wjco.v2.i3.135] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 208 |
Haefner M, Bluethner T, Niederhagen M, Moebius C, Wittekind C, Mossner J, Caca K, Wiedmann M. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol 2008; 14(23): 3681-3692 [PMID: 18595135 DOI: 10.3748/wjg.14.3681] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 209 |
Ni F, Tang H, Wang C, Zhang H, Zheng C, Zhang N, Chen B, Sun L. Baohuoside I Inhibits the Proliferation of Pancreatic Cancer Cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling. Cancer Manag Res 2019;11:10609-21. [PMID: 31908533 DOI: 10.2147/CMAR.S228926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 210 |
Kannaiyan R, Mahadevan D. A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther 2018;18:1249-70. [PMID: 30259761 DOI: 10.1080/14737140.2018.1527688] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 14.3] [Reference Citation Analysis]
|
| 211 |
Moss RA, Lee C. Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther 2010;3:111-27. [PMID: 20856847 DOI: 10.2147/ott.s7203] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 212 |
Ni X, Long J, Cen P, Chen L, Yang J, Li M. Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. J Cell Mol Med 2012;16:988-94. [PMID: 22050663 DOI: 10.1111/j.1582-4934.2011.01478.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 213 |
Candelaria NR, Addanki S, Zheng J, Nguyen-Vu T, Karaboga H, Dey P, Gabbi C, Vedin LL, Liu K, Wu W, Jonsson PK, Lin JZ, Su F, Bollu LR, Hodges SE, McElhany AL, Issazadeh MA, Fisher WE, Ittmann MM, Steffensen KR, Gustafsson JÅ, Lin CY. Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal adenocarcinoma cells. PLoS One 2014;9:e106289. [PMID: 25184494 DOI: 10.1371/journal.pone.0106289] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 214 |
Sangwan V, Banerjee S, Jensen KM, Chen Z, Chugh R, Dudeja V, Vickers SM, Saluja AK. Primary and liver metastasis-derived cell lines from KrasG12D; Trp53R172H; Pdx-1 Cre animals undergo apoptosis in response to triptolide. Pancreas 2015;44:583-9. [PMID: 25875797 DOI: 10.1097/MPA.0000000000000317] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 215 |
Wong HH, Lemoine NR. Biological approaches to therapy of pancreatic cancer. Pancreatology. 2008;8:431-461. [PMID: 18724071 DOI: 10.1159/000151536] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 216 |
Maraveyas A, Johnson M. Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Br J Cancer 2009;100:1837-41. [PMID: 19491905 DOI: 10.1038/sj.bjc.6605091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 217 |
Tactacan CM, Chang DK, Cowley MJ, Humphrey ES, Wu J, Gill AJ, Chou A, Nones K, Grimmond SM, Sutherland RL, Biankin AV, Daly RJ; Australian Pancreratic Genome Initiative. RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer. 2012;12:395. [PMID: 22958871 DOI: 10.1186/1471-2407-12-395] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 218 |
Sharma MR, Schilsky RL. GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy. Nat Rev Clin Oncol 2011;8:70-2. [PMID: 21278772 DOI: 10.1038/nrclinonc.2010.219] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 219 |
Zhou Y, Huang J, Yu X, Jiang X, Shi Y, Weng Y, Kuai Y, Lei L, Ren G, Feng X, Zhong G, Liu Q, Pan H, Zhang X, Zhou R, Lu C. LITAF is a potential tumor suppressor in pancreatic cancer. Oncotarget 2018;9:3131-42. [PMID: 29423035 DOI: 10.18632/oncotarget.23220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 220 |
Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2784-2796. [PMID: 27247222 DOI: 10.1200/jco.2016.67.1412] [Cited by in Crossref: 166] [Cited by in F6Publishing: 90] [Article Influence: 27.7] [Reference Citation Analysis]
|
| 221 |
Melisi D, Ossovskaya V, Zhu C, Rosa R, Ling J, Dougherty PM, Sherman BM, Abbruzzese JL, Chiao PJ. Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. Clin Cancer Res 2009;15:6367-77. [PMID: 19808866 DOI: 10.1158/1078-0432.CCR-09-0910] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 222 |
Stark JL, Mehla K, Chaika N, Acton TB, Xiao R, Singh PK, Montelione GT, Powers R. Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancer. Biochemistry 2014;53:1360-72. [PMID: 24512202 DOI: 10.1021/bi401329a] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 223 |
Forero-Torres A, Infante JR, Waterhouse D, Wong L, Vickers S, Arrowsmith E, He AR, Hart L, Trent D, Wade J, Jin X, Wang Q, Austin T, Rosen M, Beckman R, von Roemeling R, Greenberg J, Saleh M. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer. Cancer Med 2013;2:925-32. [PMID: 24403266 DOI: 10.1002/cam4.137] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 224 |
Nishiofuku H, Tanaka T, Marugami N, Sho M, Akahori T, Nakajima Y, Kichikawa K. Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer. Eur Radiol 2016;26:1835-42. [PMID: 26385808 DOI: 10.1007/s00330-015-3999-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 225 |
Whipple C, Korc M. Targeting angiogenesis in pancreatic cancer: rationale and pitfalls. Langenbecks Arch Surg. 2008;393:901-910. [PMID: 18210149 DOI: 10.1007/s00423-008-0280-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 226 |
Mohammad AA. Advanced pancreatic cancer: The standard of care and new opportunities. Oncol Rev 2018;12:370. [PMID: 30344961 DOI: 10.4081/oncol.2018.370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 227 |
Mehta VK. Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence. Front Oncol 2012;2:31. [PMID: 22645717 DOI: 10.3389/fonc.2012.00031] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 228 |
Hashim YM, Vangveravong S, Sankpal NV, Binder PS, Liu J, Goedegebuure SP, Mach RH, Spitzer D, Hawkins WG. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. J Exp Clin Cancer Res 2017;36:14. [PMID: 28095907 DOI: 10.1186/s13046-016-0470-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 229 |
Pelzer U, Sinn M, Stieler J, Riess H. [Multimodal treatment of pancreatic cancer]. Internist (Berl). 2014;55:31-36. [PMID: 24399472 DOI: 10.1007/s00108-013-3316-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 230 |
Iovanna J. Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. Transl Oncol 2021;14:100965. [PMID: 33248412 DOI: 10.1016/j.tranon.2020.100965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 231 |
Garrido-Laguna I, Tometich D, Hu N, Ying J, Geiersbach K, Whisenant J, Wang K, Ross JS, Sharma S. N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience 2015;2:285-93. [PMID: 25897431 DOI: 10.18632/oncoscience.141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 232 |
Sun J, Chen L, Dong M. MiR-338-5p Inhibits EGF-Induced EMT in Pancreatic Cancer Cells by Targeting EGFR/ERK Signaling. Front Oncol 2021;11:616481. [PMID: 33937024 DOI: 10.3389/fonc.2021.616481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 233 |
Bar-Ad V, Zhang QE, Harari PM, Axelrod R, Rosenthal DI, Trotti A, Jones CU, Garden AS, Song G, Foote RL, Raben D, Shenouda G, Spencer SA, Harris J, Le QT. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. Int J Radiat Oncol Biol Phys 2016;95:1346-54. [PMID: 27212198 DOI: 10.1016/j.ijrobp.2016.03.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 234 |
Du J, Gu J, Li J. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Biosci Rep 2020;40:BSR20200401. [PMID: 32677676 DOI: 10.1042/BSR20200401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 235 |
Muramatsu M, Tsuchiya A, Ohta S, Iijima Y, Maruyama M, Onodera Y, Hagihara M, Nakaya N, Sato I, Omura K, Ueno S, Nakajima H. Measuring body composition using the bioelectrical impedance method can predict the outcomes of gemcitabine-based chemotherapy in patients with pancreatobiliary tract cancer. Oncol Lett 2015;10:3535-41. [PMID: 26788165 DOI: 10.3892/ol.2015.3811] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 236 |
Chadha AS, Skinner HD, Gunther JR, Munsell MF, Das P, Minsky BD, Delclos ME, Chatterjee D, Wang H, Clemons M, George G, Singh PK, Katz MH, Fleming JB, Javle MM, Wolff RA, Varadhachary GR, Crane CH, Krishnan S. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One 2016;11:e0156910. [PMID: 27336466 DOI: 10.1371/journal.pone.0156910] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 237 |
Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases 2018;6:E103. [PMID: 30428574 DOI: 10.3390/diseases6040103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 238 |
Cardin DB, Goff LW, Chan E, Whisenant JG, Dan Ayers G, Takebe N, Arlinghaus LR, Yankeelov TE, Berlin J, Merchant N. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 2018;36:442-50. [PMID: 28990119 DOI: 10.1007/s10637-017-0519-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 239 |
Kimple RJ, Russo S, Monjazeb A, Blackstock AW. The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Rev Anticancer Ther 2012;12:469-80. [PMID: 22500684 DOI: 10.1586/era.12.18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 240 |
Nakamura T, Katagiri T, Sato S, Kushibiki T, Hontani K, Tsuchikawa T, Hirano S, Nakamura Y. Overexpression of C16orf74 is involved in aggressive pancreatic cancers. Oncotarget 2017;8:50460-75. [PMID: 28881575 DOI: 10.18632/oncotarget.10912] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 241 |
Polireddy K, Dong R, Reed G, Yu J, Chen P, Williamson S, Violet PC, Pessetto Z, Godwin AK, Fan F, Levine M, Drisko JA, Chen Q. High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study. Sci Rep 2017;7:17188. [PMID: 29215048 DOI: 10.1038/s41598-017-17568-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
|
| 242 |
Javle M, Hsueh CT. Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 2009;2:9. [PMID: 19236713 DOI: 10.1186/1756-8722-2-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 243 |
Nakata B, Amano R, Nakao S, Tamura T, Shinto O, Hirakawa T, Okita Y, Yamada N, Hirakawa K. Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer. J Exp Clin Cancer Res 2010;29:15. [PMID: 20181235 DOI: 10.1186/1756-9966-29-15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 244 |
Rodrigues CA, Ferrarotto R, Kalil Filho R, Novis YA, Hoff PM. Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis 2010;30:67-78. [PMID: 20140479 DOI: 10.1007/s11239-010-0441-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 245 |
Smigiel JM, Parameswaran N, Jackson MW. Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics. Cancers (Basel) 2018;10:E14. [PMID: 29320425 DOI: 10.3390/cancers10010014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 246 |
Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011;10:351-64. [PMID: 21532565 DOI: 10.1038/nrd3374] [Cited by in Crossref: 194] [Cited by in F6Publishing: 172] [Article Influence: 17.6] [Reference Citation Analysis]
|
| 247 |
Haj Mohammad N, Bernards N, Besselink MG, Busch OR, Wilmink JW, Creemers GJ, De Hingh IH, Lemmens VE, van Laarhoven HW. Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands. J Cancer Res Clin Oncol 2016;142:1353-60. [PMID: 26995276 DOI: 10.1007/s00432-016-2140-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 248 |
Brunetti O, Badalamenti G, De Summa S, Calabrese A, Argentiero A, Fucci L, Longo V, Galetta D, Perrotti PMS, Pinto R, Petriella D, Danza K, Tommasi S, Leonetti F, Silvestris N. Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Cancers (Basel) 2019;11:E749. [PMID: 31146476 DOI: 10.3390/cancers11060749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 249 |
Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. J Gastrointest Cancer 2013;44:182-9. [PMID: 23208490 DOI: 10.1007/s12029-012-9466-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 250 |
Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors’ down-regulation and dimers’ disruption. Neoplasia. 2012;14:121-130. [PMID: 22431920 DOI: 10.1593/neo.111602] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 251 |
Kyrochristos ID, Glantzounis GK, Ziogas DE, Gizas I, Schizas D, Lykoudis EG, Felekouras E, Machairas A, Katsios C, Liakakos T, Cho WC, Roukos DH. From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci 2017;18:E180. [PMID: 28106782 DOI: 10.3390/ijms18010180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 252 |
Tam VC, Ko YJ, Mittmann N, Cheung MC, Kumar K, Hassan S, Chan KK. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol. 2013;20:e90-e106. [PMID: 23559890 DOI: 10.3747/co.20.1223] [Cited by in Crossref: 28] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 253 |
Watanabe T, Ueno H, Watabe Y, Hiraoka N, Morizane C, Itami J, Okusaka T, Miura N, Kakizaki T, Kakuya T, Kamita M, Tsuchida A, Nagakawa Y, Wilber H, Yamada T, Honda K. ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer. Br J Cancer 2015;112:704-13. [PMID: 25602965 DOI: 10.1038/bjc.2014.623] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 254 |
Gayral M, Lulka H, Hanoun N, Biollay C, Sèlves J, Vignolle-Vidoni A, Berthommé H, Trempat P, Epstein AL, Buscail L, Béjot JL, Cordelier P. Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors. Hum Gene Ther 2015;26:104-13. [PMID: 25423447 DOI: 10.1089/hum.2014.072] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 255 |
Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, Khazak V, Jablonski SA, Golemis EA, Weiner LM, Astsaturov I. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer. Clin Cancer Res 2016;22:6153-63. [PMID: 27384421 DOI: 10.1158/1078-0432.CCR-16-0149] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 256 |
Borsoi C, Leonard F, Lee Y, Zaid M, Elganainy D, Alexander JF, Kai M, Liu YT, Kang Y, Liu X, Koay EJ, Ferrari M, Godin B, Yokoi K. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Lett 2017;403:296-304. [PMID: 28687352 DOI: 10.1016/j.canlet.2017.06.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 257 |
von der Heyde S, Bender C, Henjes F, Sonntag J, Korf U, Beißbarth T. Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines. BMC Syst Biol 2014;8:75. [PMID: 24970389 DOI: 10.1186/1752-0509-8-75] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 258 |
Thomas R, Weihua Z. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. Front Oncol 2019;9:800. [PMID: 31508364 DOI: 10.3389/fonc.2019.00800] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 259 |
Fotopoulos G, Syrigos K, Saif MW. Genetic factors affecting patient responses to pancreatic cancer treatment. Ann Gastroenterol 2016;29:466-76. [PMID: 27708512 DOI: 10.20524/aog.2016.0056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 260 |
Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101:1044-8. [PMID: 19564563 DOI: 10.1093/jnci/djp177] [Cited by in Crossref: 261] [Cited by in F6Publishing: 214] [Article Influence: 20.1] [Reference Citation Analysis]
|
| 261 |
Campbell PM, Boufaied N, Fiordalisi JJ, Cox AD, Falardeau P, Der CJ, Gourdeau H. TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling. J Mol Signal 2010;5:18. [PMID: 21044336 DOI: 10.1186/1750-2187-5-18] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 262 |
Zhang H. Onivyde for the therapy of multiple solid tumors. Onco Targets Ther 2016;9:3001-7. [PMID: 27284250 DOI: 10.2147/OTT.S105587] [Cited by in Crossref: 64] [Cited by in F6Publishing: 24] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 263 |
Rutkowska A, Stoczyńska-Fidelus E, Janik K, Włodarczyk A, Rieske P. EGFRvIII: An Oncogene with Ambiguous Role. J Oncol 2019;2019:1092587. [PMID: 32089685 DOI: 10.1155/2019/1092587] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 264 |
Lo Re G, Santeufemia DA, Foltran L, Bidoli E, Basso SM, Lumachi F. Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience. Oncotarget 2015;6:8255-60. [PMID: 25779664 DOI: 10.18632/oncotarget.3143] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 265 |
Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G. State of the art biological therapies in pancreatic cancer. World J Gastrointest Oncol 2016; 8(1): 55-66 [PMID: 26798437 DOI: 10.4251/wjgo.v8.i1.55] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 266 |
Sanomachi T, Suzuki S, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C, Yamamoto M. Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs. Cancers (Basel) 2019;11:E1550. [PMID: 31614999 DOI: 10.3390/cancers11101550] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 267 |
Zhang X, Detering L, Sultan D, Luehmann H, Li L, Heo GS, Zhang X, Lou L, Grierson PM, Greco S, Ruzinova M, Laforest R, Dehdashti F, Lim KH, Liu Y. CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. ACS Nano 2021;15:1186-98. [PMID: 33406361 DOI: 10.1021/acsnano.0c08185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 268 |
Kim H, Zhai G, Liu Z, Samuel S, Shah N, Helman EE, Knowles JA, Stockard CR, Fineberg NS, Grizzle WE, Zhou T, Zinn KR, Rosenthal EL. Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy. Anticancer Drugs 2011;22:864-74. [PMID: 21730821 DOI: 10.1097/CAD.0b013e328349311e] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 269 |
Aprile G, Rihawi K, De Carlo E, Sonis ST. Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. World J Gastroenterol 2015; 21(41): 11793-11803 [PMID: 26557003 DOI: 10.3748/wjg.v21.i41.11793] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 270 |
Li M, Yu X, Guo H, Sun L, Wang A, Liu Q, Wang X, Li J. Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells. Tumour Biol. 2014;35:2461-2471. [PMID: 24218335 DOI: 10.1007/s13227-013-1326-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 271 |
Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010;60:222-243. [PMID: 20554717 DOI: 10.3322/caac.20075] [Cited by in Crossref: 311] [Cited by in F6Publishing: 273] [Article Influence: 25.9] [Reference Citation Analysis]
|
| 272 |
Hegewisch-Becker S, Aldaoud A, Wolf T, Krammer-Steiner B, Linde H, Scheiner-Sparna R, Hamm D, Jänicke M, Marschner N; TPK-Group (Tumour Registry Pancreatic Cancer). Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. Int J Cancer 2019;144:981-90. [PMID: 30006989 DOI: 10.1002/ijc.31751] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 273 |
Heestand GM, Kurzrock R. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget 2015;6:4553-61. [PMID: 25714017 DOI: 10.18632/oncotarget.2972] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 274 |
Lakatos G, Tulassay Z. [Antiangiogenic therapy for gastrointestinal tumors]. Orv Hetil 2008;149:2317-24. [PMID: 19042183 DOI: 10.1556/OH.2008.28496] [Reference Citation Analysis]
|
| 275 |
Hua J, Shi S, Liang D, Liang C, Meng Q, Zhang B, Ni Q, Xu J, Yu X. Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining? Onco Targets Ther 2018;11:4591-608. [PMID: 30122951 DOI: 10.2147/OTT.S166405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 276 |
Meng H, Wang M, Liu H, Liu X, Situ A, Wu B, Ji Z, Chang CH, Nel AE. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano. 2015;9:3540-3557. [PMID: 25776964 DOI: 10.1021/acsnano.5b00510] [Cited by in Crossref: 254] [Cited by in F6Publishing: 231] [Article Influence: 36.3] [Reference Citation Analysis]
|
| 277 |
Popa EC, Shah MA. Met, IGF1R, and other new targets in upper GI malignancies. Curr Treat Options Oncol. 2013;14:321-336. [PMID: 23873272 DOI: 10.1007/s11864-013-0245-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 278 |
Kandimalla R, Tomihara H, Banwait JK, Yamamura K, Singh G, Baba H, Goel A. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26:3641-8. [PMID: 32234757 DOI: 10.1158/1078-0432.CCR-19-4044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 279 |
Chabu C, Li DM, Xu T. EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth. Nat Commun 2017;8:14688. [PMID: 28281543 DOI: 10.1038/ncomms14688] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 280 |
Takano S, Sogawa K, Yoshitomi H, Shida T, Mogushi K, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A. Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. Br J Cancer. 2010;103:223-231. [PMID: 20551957 DOI: 10.1038/sj.bjc.6605734] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 281 |
Gopal S, Kwon SJ, Ku B, Lee DW, Kim J, Dordick JS. 3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity. Commun Biol 2021;4:893. [PMID: 34290356 DOI: 10.1038/s42003-021-02417-2] [Reference Citation Analysis]
|
| 282 |
Au M, Emeto TI, Power J, Vangaveti VN, Lai HC. Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials. Biomedicines 2016;4:E20. [PMID: 28536387 DOI: 10.3390/biomedicines4030020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 283 |
Iwai T, Moriya Y, Shirane M, Fujimoto-Ouchi K, Mori K. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts. Oncol Rep 2012;27:923-8. [PMID: 22209766 DOI: 10.3892/or.2011.1614] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 284 |
Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Adjuvant and neoadjuvant treatment in pancreatic cancer. World J Gastroenterol 2012; 18(14): 1565-1572 [PMID: 22529684 DOI: 10.3748/wjg.v18.i14.1565] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 285 |
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 849] [Article Influence: 125.2] [Reference Citation Analysis]
|
| 286 |
Berger AK, Haag GM, Ehmann M, Byl A, Jäger D, Springfeld C. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. BMC Gastroenterol 2017;17:143. [PMID: 29207968 DOI: 10.1186/s12876-017-0709-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 287 |
Sempere LF, Gunn JR, Korc M. A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells. Cancer Biol Ther 2011;12:198-207. [PMID: 21613822 DOI: 10.4161/cbt.12.3.15979] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 288 |
Liquete E, Ali S, Kammo R, Ali M, Alali F, Challa H, Fata F. Acute Generalized Exanthematous Pustulosis Induced by Erlotinib (Tarceva) with Superimposed Staphylococcus aureus Skin Infection in a Pancreatic Cancer Patient: A Case Report. Case Rep Oncol 2012;5:253-9. [PMID: 22712013 DOI: 10.1159/000338806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 289 |
Awasthi N, Schwarz MA, Schwarz RE. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. HPB (Oxford) 2011;13:597-604. [PMID: 21843259 DOI: 10.1111/j.1477-2574.2011.00333.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 290 |
Xu H, Chen R, Shen Q, Yang D, Peng H, Tong J, Fu Q. Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway. Front Oncol 2021;11:754146. [PMID: 34552882 DOI: 10.3389/fonc.2021.754146] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 291 |
Papademetrio DL, Cavaliere V, Simunovich T, Costantino S, Campos MD, Lombardo T, Kaiser CM, Alvarez E. Interplay between autophagy and apoptosis in pancreatic tumors in response to gemcitabine. Target Oncol 2014;9:123-34. [PMID: 23588416 DOI: 10.1007/s11523-013-0278-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 292 |
Brown AP, Citrin DE, Camphausen KA. Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Rev 2008;27:415-34. [PMID: 18414993 DOI: 10.1007/s10555-008-9143-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 293 |
Dahl O, Borkamo ED, Fluge O. Current status of antivascular therapy and targeted treatment in the clinic. Int J Hyperthermia 2008;24:97-110. [PMID: 18214773 DOI: 10.1080/02656730701824406] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 294 |
Ang C, Doyle E, Branch A. Bisphosphonates as potential adjuvants for patients with cancers of the digestive system. World J Gastroenterol 2016; 22(3): 906-916 [PMID: 26811636 DOI: 10.3748/wjg.v22.i3.906] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 295 |
Skelton WP 4th, Parekh H, Starr JS, Trevino J, Cioffi J, Hughes S, George TJ Jr. Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. J Gastrointest Cancer 2018;49:1-8. [PMID: 29110227 DOI: 10.1007/s12029-017-0021-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 296 |
Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 310] [Article Influence: 28.2] [Reference Citation Analysis]
|
| 297 |
Kang MJ, Jang JY, Lee SE, Lim CS, Lee KU, Kim SW. Comparison of the long-term outcomes of uncinate process cancer and non-uncinate process pancreas head cancer: poor prognosis accompanied by early locoregional recurrence. Langenbecks Arch Surg. 2010;395:697-706. [PMID: 20652784 DOI: 10.1007/s00423-010-0593-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 298 |
Michaelson MD, Zhu AX, Ryan DP, McDermott DF, Shapiro GI, Tye L, Chen I, Stephenson P, Patyna S, Ruiz-Garcia A, Schwarzberg AB. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Br J Cancer 2013;108:1393-401. [PMID: 23511559 DOI: 10.1038/bjc.2013.96] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 299 |
Chabot JA, Tsai WY, Fine RL, Chen C, Kumah CK, Antman KA, Grann VR. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol 2010;28:2058-63. [PMID: 19687327 DOI: 10.1200/JCO.2009.22.8429] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 300 |
Madamsetty VS, Pal K, Dutta SK, Wang E, Mukhopadhyay D. Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer. Cancers (Basel) 2020;12:E1189. [PMID: 32397114 DOI: 10.3390/cancers12051189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 301 |
Quintela-Fandino M, Le Tourneau C, Duran I, Chen EX, Wang L, Tsao M, Bandarchi-Chamkhaleh B, Pham NA, Do T, MacLean M, Nayyar R, Tusche MW, Metser U, Wright JJ, Mak TW, Siu LL. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Mol Cancer Ther 2010;9:751-60. [PMID: 20197396 DOI: 10.1158/1535-7163.MCT-09-0868] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 302 |
Han B, Kim BJ, Kim HS, Choi DR, Shim BY, Lee KH, Kim JW, Kim JH, Song H, Kim JH, Park CK, Lee JW, Kim MJ, Zang DY. A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. J Cancer 2021;12:912-7. [PMID: 33403047 DOI: 10.7150/jca.50514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 303 |
Zheng YT, Yang HY, Li T, Zhao B, Shao TF, Xiang XQ, Cai WM. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Acta Pharmacol Sin. 2015;36:614-626. [PMID: 25864651 DOI: 10.1038/aps.2015.4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 304 |
Witkiewicz AK, Borja NA, Franco J, Brody JR, Yeo CJ, Mansour J, Choti MA, McCue P, Knudsen ES. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget 2015;6:15788-801. [PMID: 26158861 DOI: 10.18632/oncotarget.3819] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 305 |
Pelzer U, Hilbig A, Stieler JM, Bahra M, Sinn M, Gebauer B, Dörken B, Riess H. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer 2014;14:204. [PMID: 24641937 DOI: 10.1186/1471-2407-14-204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 306 |
Schultheis B, Strumberg D, Bergmann L, Graeven U, Hanauske AR, Lipp R, Schuette J, Saito K, Scigalla P, Scheulen ME. Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). Invest New Drugs. 2012;30:1184-1192. [PMID: 21484249 DOI: 10.1007/s10637-011-9665-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 307 |
Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 2013;31:1405-14. [PMID: 23460714 DOI: 10.1200/JCO.2012.45.4272] [Cited by in Crossref: 148] [Cited by in F6Publishing: 51] [Article Influence: 16.4] [Reference Citation Analysis]
|
| 308 |
Humbert M, Castéran N, Letard S, Hanssens K, Iovanna J, Finetti P, Bertucci F, Bader T, Mansfield CD, Moussy A. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS One. 2010;5:e9430. [PMID: 20209107 DOI: 10.1371/journal.pone.0009430] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 309 |
Gutt R, Liauw SL, Weichselbaum RR. The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol. 2010;7:437-447. [PMID: 20628346 DOI: 10.1038/nrgastro.2010.98] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 310 |
Oria VO, Bronsert P, Thomsen AR, Föll MC, Zamboglou C, Hannibal L, Behringer S, Biniossek ML, Schreiber C, Grosu AL, Bolm L, Rades D, Keck T, Werner M, Wellner UF, Schilling O. Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance. Transl Oncol 2018;11:1307-22. [PMID: 30172883 DOI: 10.1016/j.tranon.2018.08.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 311 |
Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, Radosevic-Robin N, Penault-Llorca F, Gongora C, Colombo PE, Lazrek Y, Bras-Goncalves R, Savina A, Azria D, Bazin H, Pèlegrin A, Larbouret C. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget 2014;5:7138-48. [PMID: 25216528 DOI: 10.18632/oncotarget.2231] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 312 |
Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol Cancer Ther. 2013;12:2213-2225. [PMID: 23918833 DOI: 10.1158/1535-7163.mct-13-0104] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 313 |
van Roey R, Brabletz T, Stemmler MP, Armstark I. Deregulation of Transcription Factor Networks Driving Cell Plasticity and Metastasis in Pancreatic Cancer. Front Cell Dev Biol 2021;9:753456. [PMID: 34888306 DOI: 10.3389/fcell.2021.753456] [Reference Citation Analysis]
|
| 314 |
Fasano M, Della Corte CM, Vicidomini G, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F, Morgillo F. Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review. Oncol Lett 2016;12:4505-9. [PMID: 28105159 DOI: 10.3892/ol.2016.5279] [Reference Citation Analysis]
|
| 315 |
Aggarwal BB, Danda D, Gupta S, Gehlot P. Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol. 2009;78:1083-1094. [PMID: 19481061 DOI: 10.1016/j.bcp.2009.05.027] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 316 |
Park JK, Lee JH, Noh DH, Park JK, Lee KT, Lee JK, Lee KH, Jang KT, Cho J. Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma. Gut Liver 2020;14:387-94. [PMID: 31581388 DOI: 10.5009/gnl19011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 317 |
Rosenberg A, Mahalingam D. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. J Gastrointest Oncol. 2018;9:143-159. [PMID: 29564181 DOI: 10.21037/jgo.2018.01.13] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 318 |
Poteet E, Liu D, Liang Z, Van Buren G, Chen C, Yao Q. Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib. PLoS One 2019;14:e0213294. [PMID: 30921351 DOI: 10.1371/journal.pone.0213294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 319 |
Peretti U, Zanon S, Michele R. The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective. Endosc Ultrasound 2017;6:S66-8. [PMID: 29387692 DOI: 10.4103/eus.eus_62_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 320 |
Raufi AG, Liguori NR, Carlsen L, Parker C, Hernandez Borrero L, Zhang S, Tian X, Louie A, Zhou L, Seyhan AA, El-deiry WS. Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma. Front Pharmacol 2021;12:751568. [DOI: 10.3389/fphar.2021.751568] [Reference Citation Analysis]
|
| 321 |
Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res. 2006;12:4283-4287. [PMID: 16857803 DOI: 10.1158/1078-0432.ccr-06-0189] [Cited by in Crossref: 114] [Cited by in F6Publishing: 59] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 322 |
Lu YY, Jing DD, Xu M, Wu K, Wang XP. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World J Gastroenterol 2008; 14(35): 5403-5411 [PMID: 18803351 DOI: 10.3748/wjg.14.5403] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 323 |
Breuer S, Maimon O, Appelbaum L, Peretz T, Hubert A. TL-118-anti-angiogenic treatment in pancreatic cancer: a case report. Med Oncol 2013;30:585. [PMID: 23609193 DOI: 10.1007/s12032-013-0585-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 324 |
Dhayat SA, Yang Z. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. J Cancer Res Clin Oncol 2020;146:1625-45. [PMID: 32338295 DOI: 10.1007/s00432-020-03219-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 325 |
Liu X, Pitarresi JR, Cuitiño MC, Kladney RD, Woelke SA, Sizemore GM, Nayak SG, Egriboz O, Schweickert PG, Yu L, Trela S, Schilling DJ, Halloran SK, Li M, Dutta S, Fernandez SA, Rosol TJ, Lesinski GB, Shakya R, Ludwig T, Konieczny SF, Leone G, Wu J, Ostrowski MC. Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar-ductal metaplasia. Genes Dev 2016;30:1943-55. [PMID: 27633013 DOI: 10.1101/gad.283499.116] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 326 |
Yoshida M, Takimoto R, Murase K, Sato Y, Hirakawa M, Tamura F, Sato T, Iyama S, Osuga T, Miyanishi K, Takada K, Hayashi T, Kobune M, Kato J. Targeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approach. PLoS One 2012;7:e39545. [PMID: 22808043 DOI: 10.1371/journal.pone.0039545] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 327 |
Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T, Hanna N, Chang KJ, Javle M, Posner M, Waxman I, Reid A, Erickson R, Canto M, Chak A, Blatner G, Kovacevic M, Thornton M. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc 2012;75:332-8. [PMID: 22248601 DOI: 10.1016/j.gie.2011.10.007] [Cited by in Crossref: 92] [Cited by in F6Publishing: 75] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 328 |
Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B, Grunt TW, Zielinski CC, Valent P. Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol 2015;8:16. [PMID: 25886184 DOI: 10.1186/s13045-015-0113-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 329 |
Seufferlein T, Ahn J, Krndija D, Lother U, Adler G, von Wichert G. Tumor biology and cancer therapy - an evolving relationship. Cell Commun Signal 2009;7:19. [PMID: 19678929 DOI: 10.1186/1478-811X-7-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 330 |
Infante JR, Arkenau HT, Bendell JC, Rubin MS, Waterhouse D, Jones GT, Spigel DR, Lane CM, Hainsworth JD, Burris HA 3rd. Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial. Cancer Biol Ther 2013;14:340-6. [PMID: 23358470 DOI: 10.4161/cbt.23625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 331 |
Quispe-Tintaya W, Chandra D, Jahangir A, Harris M, Casadevall A, Dadachova E, Gravekamp C. Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci U S A 2013;110:8668-73. [PMID: 23610422 DOI: 10.1073/pnas.1211287110] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 332 |
Weinstein MC, Skinner JA. Comparative effectiveness and health care spending--implications for reform. N Engl J Med 2010;362:460-5. [PMID: 20054039 DOI: 10.1056/NEJMsb0911104] [Cited by in Crossref: 167] [Cited by in F6Publishing: 52] [Article Influence: 13.9] [Reference Citation Analysis]
|
| 333 |
Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB 3rd. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 2010;101:587-92. [PMID: 20461765 DOI: 10.1002/jso.21527] [Cited by in Crossref: 118] [Cited by in F6Publishing: 100] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 334 |
Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009;27:5506-5512. [PMID: 19858396 DOI: 10.1200/jco.2009.22.1309] [Cited by in Crossref: 58] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 335 |
Goedegebuure P, Mitchem JB, Porembka MR, Tan MC, Belt BA, Wang-Gillam A, Gillanders WE, Hawkins WG, Linehan DC. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets. 2011;11:734-751. [PMID: 21599634 DOI: 10.2174/156800911796191024] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 336 |
Bobrov E, Skobeleva N, Restifo D, Beglyarova N, Cai KQ, Handorf E, Campbell K, Proia DA, Khazak V, Golemis EA, Astsaturov I. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. Oncotarget 2017;8:4399-409. [PMID: 27779106 DOI: 10.18632/oncotarget.12642] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 337 |
Huang ZQ, Buchsbaum DJ. Monoclonal antibodies in the treatment of pancreatic cancer. Immunotherapy. 2009;1:223-229. [PMID: 20046965 DOI: 10.2217/1750743x.1.2.223] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 338 |
Awad S, Alkashash AM, Amin M, Baker SJ, Rose JB. Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Front Oncol 2020;10:620. [PMID: 32477933 DOI: 10.3389/fonc.2020.00620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 339 |
Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS; Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 340 |
Uzunparmak B, Sahin IH. Pancreatic cancer microenvironment: a current dilemma. Clin Transl Med 2019;8:2. [PMID: 30645701 DOI: 10.1186/s40169-019-0221-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 341 |
Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 2012;7:e29794. [PMID: 22272248 DOI: 10.1371/journal.pone.0029794] [Cited by in Crossref: 138] [Cited by in F6Publishing: 132] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 342 |
Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
|
| 343 |
Ottenhof NA, de Wilde RF, Maitra A, Hruban RH, Offerhaus GJ. Molecular characteristics of pancreatic ductal adenocarcinoma. Patholog Res Int. 2011;2011:620601. [PMID: 21512581 DOI: 10.4061/2011/620601] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 344 |
De Simoni O, Scarpa M, Tonello M, Pilati P, Tolin F, Spolverato Y, Gruppo M. Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. Cancers (Basel) 2020;12:E3402. [PMID: 33213022 DOI: 10.3390/cancers12113402] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 345 |
Patra CR, Bhattacharya R, Mukhopadhyay D, Mukherjee P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev 2010;62:346-61. [PMID: 19914317 DOI: 10.1016/j.addr.2009.11.007] [Cited by in Crossref: 271] [Cited by in F6Publishing: 222] [Article Influence: 20.8] [Reference Citation Analysis]
|
| 346 |
Serda M, Malarz K, Mrozek-Wilczkiewicz A, Wojtyniak M, Musioł R, Curley SA. Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment. Sci Rep 2020;10:260. [PMID: 31937861 DOI: 10.1038/s41598-019-57155-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 347 |
Ying JE, Zhu LM, Liu BX. Developments in metastatic pancreatic cancer: Is gemcitabine still the standard? World J Gastroenterol 2012; 18(8): 736-745 [PMID: 22371633 DOI: 10.3748/wjg.v18.i8.736] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 348 |
Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, Davidson NE. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res 2008;14:6277-83. [PMID: 18829509 DOI: 10.1158/1078-0432.CCR-08-0482] [Cited by in Crossref: 56] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 349 |
Mian OY, Ram AN, Tuli R, Herman JM. Management options in locally advanced pancreatic cancer. Curr Oncol Rep 2014;16:388. [PMID: 24740136 DOI: 10.1007/s11912-014-0388-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 350 |
Fleming TR, Odem-Davis K, Rothmann MD, Li Shen Y. Some essential considerations in the design and conduct of non-inferiority trials. Clin Trials 2011;8:432-9. [PMID: 21835862 DOI: 10.1177/1740774511410994] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 351 |
Geng M, Xu H, Ren R, Qu Q, Shangguan C, Wu J, Jiang J, Li H, Cao W. Prognostic value of clinicopathological characteristics in patients with pancreatic cancer. Chin J Cancer Res 2015;27:509-15. [PMID: 26543338 DOI: 10.3978/j.issn.1000-9604.2015.06.03] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 352 |
Maraveyas A. Pancreatic cancer: A model cancer for the study of the therapeutic effects of anticoagulants. World J Gastrointest Oncol 2009; 1(1): 38-40 [PMID: 21160772 DOI: 10.4251/wjgo.v1.i1.38] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 353 |
Yang ZY, Yuan JQ, Di MY, Zheng DY, Chen JZ, Ding H, Wu XY, Huang YF, Mao C, Tang JL. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One. 2013;8:e57528. [PMID: 23472089 DOI: 10.1371/journal.pone.0057528] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 354 |
Yoong J, Michael M, Leong T. Targeted therapies for gastric cancer: current status. Drugs. 2011;71:1367-1384. [PMID: 21812503 DOI: 10.2165/11592530-000000000-00000] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 355 |
Liles JS, Arnoletti JP, Tzeng CW, Howard JH, Kossenkov AV, Kulesza P, Heslin MJ, Frolov A. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biol Ther. 2010;10:555-563. [PMID: 20647770 DOI: 10.4161/cbt.10.6.12532] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 356 |
Venkatesha VA, Parsels LA, Parsels JD, Zhao L, Zabludoff SD, Simeone DM, Maybaum J, Lawrence TS, Morgan MA. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia 2012;14:519-25. [PMID: 22787433 DOI: 10.1593/neo.12538] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 357 |
Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med. 2014;3:406-415. [PMID: 24519894 DOI: 10.1002/cam4.204] [Cited by in Crossref: 74] [Cited by in F6Publishing: 79] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 358 |
Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, Kopek N, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol 2016;23:e605-14. [PMID: 28050151 DOI: 10.3747/co.23.3394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 359 |
Wu Q, Li ZS. Molecular targeted therapy of digestive system neoplasms. Shijie Huaren Xiaohua Zazhi 2008; 16(32): 3666-3672 [DOI: 10.11569/wcjd.v16.i32.3666] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 360 |
Li LY, Jiang H, Xie YM, Liao LD, Cao HH, Xu XE, Chen B, Zeng FM, Zhang YL, Du ZP, Chen H, Huang W, Jia W, Zheng W, Xie JJ, Li EM, Xu LY. Macrolide analog F806 suppresses esophageal squamous cell carcinoma (ESCC) by blocking β1 integrin activation. Oncotarget 2015;6:15940-52. [PMID: 25909284 DOI: 10.18632/oncotarget.3612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 361 |
Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, Kinoshita S, Nagai M, Konishi N, Nakajima Y. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res 2015;34:30. [PMID: 25888293 DOI: 10.1186/s13046-015-0144-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 362 |
Schwartzberg LS, Arena FP, Bienvenu BJ, Kaplan EH, Camacho LH, Campos LT, Waymack JP, Tagliaferri MA, Chen MM, Li D. A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer. J Cancer 2017;8:1872-83. [PMID: 28819385 DOI: 10.7150/jca.15407] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 363 |
Giardino A, Girelli R, Frigerio I, Regi P, Cantore M, Alessandra A, Lusenti A, Salvia R, Bassi C, Pederzoli P. Triple approach strategy for patients with locally advanced pancreatic carcinoma. HPB (Oxford) 2013;15:623-7. [PMID: 23458679 DOI: 10.1111/hpb.12027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 364 |
Duffy A, Kummar S. Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. Target Oncol 2009;4:267-73. [PMID: 19899001 DOI: 10.1007/s11523-009-0125-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 365 |
Kang CM, Babicky ML, Lowy AM. The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. Pancreas. 2014;43:183-189. [PMID: 24518495 DOI: 10.1097/mpa.0000000000000088] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 366 |
Moreno Garcia V, Thavasu P, Blanco Codesido M, Molife LR, Vitfell Pedersen J, Puglisi M, Basu B, Shah K, Iqbal J, de Bono JS, Kaye SB, Banerji U. Association of creatine kinase and skin toxicity in phase I trials of anticancer agents. Br J Cancer 2012;107:1797-800. [PMID: 23099802 DOI: 10.1038/bjc.2012.482] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 367 |
Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, Iacobuzio-Donahue C, Donehower RC, Carducci M, Rudek MA, Hidalgo M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer 2010;9:297-304. [PMID: 21208844 DOI: 10.3816/CCC.2010.n.043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 368 |
Kim S, Lahmy R, Riha C, Yang C, Jakubison BL, van Niekerk J, Staub C, Wu Y, Gates K, Dong DS. The basic helix-loop-helix transcription factor E47 reprograms human pancreatic cancer cells to a quiescent acinar state with reduced tumorigenic potential. Pancreas. 2015;44:718-727. [PMID: 25894862 DOI: 10.1097/mpa.0000000000000328] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 369 |
Baylot V, Andrieu C, Katsogiannou M, Taieb D, Garcia S, Giusiano S, Acunzo J, Iovanna J, Gleave M, Garrido C. OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis. 2011;2:e221. [PMID: 22012255 DOI: 10.1038/cddis.2011.104] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 370 |
Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72. [DOI: 10.1038/nrclinonc.2009.236] [Cited by in Crossref: 516] [Cited by in F6Publishing: 504] [Article Influence: 43.0] [Reference Citation Analysis]
|
| 371 |
Li JL, Cai Y, Zhang SW, Xiao SW, Li XF, Duan YJ, Li YH, Xu B, Yan K. Combination of Recombinant Adenovirus-p53 with Radiochemotherapy in Unresectable Pancreatic Carcinoma. Chin J Cancer Res 2011;23:194-200. [PMID: 23467436 DOI: 10.1007/s11670-011-0194-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 372 |
Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y, Mizuno S, Yamamoto K, Arizumi T, Togawa O, Matsubara S, Tsujino T, Tateishi K, Tada M, Omata M, Koike K. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 2010;103:1644-8. [PMID: 20978506 DOI: 10.1038/sj.bjc.6605955] [Cited by in Crossref: 99] [Cited by in F6Publishing: 129] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 373 |
Banerjee S, Saluja A. Minnelide, a novel drug for pancreatic and liver cancer. Pancreatology 2015;15:S39-43. [PMID: 26122306 DOI: 10.1016/j.pan.2015.05.472] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 374 |
Ali S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA, Sarkar FH. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther 2008;7:1708-19. [PMID: 18566242 DOI: 10.1158/1535-7163.MCT-08-0354] [Cited by in Crossref: 61] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 375 |
Hsueh CT. Pancreatic cancer: current standards, research updates and future directions. J Gastrointest Oncol 2011;2:123-5. [PMID: 22811841 DOI: 10.3978/j.issn.2078-6891.2011.037] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
|
| 376 |
Mehrotra S, Britten CD, Chin S, Garrett-Mayer E, Cloud CA, Li M, Scurti G, Salem ML, Nelson MH, Thomas MB, Paulos CM, Salazar AM, Nishimura MI, Rubinstein MP, Li Z, Cole DJ. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol 2017;10:82. [PMID: 28388966 DOI: 10.1186/s13045-017-0459-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 377 |
Abraham J, Nelon LD, Kubicek CB, Kilcoyne A, Hampton ST, Zarzabal LA, Giles FJ, Michalek JE, Rubin BP, Keller C. Preclinical testing of erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model. Sarcoma 2011;2011:130484. [PMID: 21559212 DOI: 10.1155/2011/130484] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 378 |
Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 2017;3:516-22. [PMID: 27978579 DOI: 10.1001/jamaoncol.2016.5383] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 15.6] [Reference Citation Analysis]
|
| 379 |
Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: An update and perspective. Drug Resist Updat 2021;:100796. [PMID: 34953682 DOI: 10.1016/j.drup.2021.100796] [Reference Citation Analysis]
|
| 380 |
Wang L, Wu H, Wang L, Lu J, Duan H, Liu X, Liang Z. Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma. Diagn Pathol 2016;11:60. [PMID: 27391842 DOI: 10.1186/s13000-016-0512-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 381 |
Chames P, Kerfelec B, Baty D. Therapeutic antibodies for the treatment of pancreatic cancer. Scientific World Journal. 2010;10:1107-1120. [PMID: 20563534 DOI: 10.1100/tsw.2010.103] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 382 |
Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R, Roose JP. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol 2015;17:804-15. [PMID: 26005835 DOI: 10.1038/ncb3175] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 383 |
Valsecchi ME, Díaz-Cantón E, de la Vega M, Littman SJ. Recent treatment advances and novel therapies in pancreas cancer: a review. J Gastrointest Cancer 2014;45:190-201. [PMID: 24343588 DOI: 10.1007/s12029-013-9561-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 384 |
Oh DY, Lee KW, Lee KH, Sohn CH, Park YS, Zang DY, Ryoo HM, Song HS, Kim JS, Kang HJ, Kim BS, Bang YJ. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Invest New Drugs 2012;30:1164-74. [PMID: 21404106 DOI: 10.1007/s10637-011-9651-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 385 |
Chu M, Wang T, Sun A, Chen Y. Nimesulide inhibits proliferation and induces apoptosis of pancreatic cancer cells by enhancing expression of PTEN. Exp Ther Med 2018;16:370-6. [PMID: 29896263 DOI: 10.3892/etm.2018.6191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 386 |
Lee JM, Lee HS, Hyun JJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Chun HJ, Um SH, Kim CD. Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol 2016; 8(7): 555-562 [PMID: 27559435 DOI: 10.4251/wjgo.v8.i7.555] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 387 |
Ady JW, Heffner J, Klein E, Fong Y. Oncolytic viral therapy for pancreatic cancer: current research and future directions. Oncolytic Virotherapy. 2014;3:35-46. [PMID: 27512661 DOI: 10.2147/ov.s53858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 388 |
Puri A, Chang J, Tanner N, Lucente P, Desiongco J, Dragovich T, Naraev B, Kundranda M. Skeletal metastases in advanced pancreatic ductal adenocarcinoma: a retrospective analysis. J Gastrointest Oncol 2021;12:455-63. [PMID: 34012639 DOI: 10.21037/jgo-20-361] [Reference Citation Analysis]
|
| 389 |
Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther. 2013;7:33-43. [PMID: 24379681 DOI: 10.2147/ott.s38111] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 390 |
Huang TC, Kar S, Javle M. Personalized therapy for pancreatic cancer: Myth or reality in 2010? J Gastrointest Oncol 2010;1:24-33. [PMID: 22811802 DOI: 10.3978/j.issn.2078-6891.2010.009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 391 |
Toyama Y, Yoshida S, Saito R, Kitamura H, Okui N, Miyake R, Ito R, Son K, Usuba T, Nojiri T, Yanaga K. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life. World J Surg Oncol 2013;11:3. [PMID: 23302293 DOI: 10.1186/1477-7819-11-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 392 |
Kieler M, Unseld M, Bianconi D, Schindl M, Kornek GV, Scheithauer W, Prager GW. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. J Clin Med. 2020;9. [PMID: 32121198 DOI: 10.3390/jcm9030648] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 393 |
Lu Z, Weniger M, Jiang K, Boeck S, Zhang K, Bazhin A, Miao Y, Werner J, D'Haese JG. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Target Oncol 2018;13:447-59. [PMID: 30062609 DOI: 10.1007/s11523-018-0578-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 394 |
Iede K, Yamada T, Kato R, Ueda M, Tsuda Y, Nakashima S, Ohta K, Matsuyama J, Ikenaga M, Tominaga S. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer. Cancer Rep (Hoboken) 2020;3:e1215. [PMID: 32672000 DOI: 10.1002/cnr2.1215] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 395 |
Koutsounas I, Giaginis C, Theocharis S. Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials? World J Gastroenterol 2013; 19(8): 1173-1181 [PMID: 23482354 DOI: 10.3748/wjg.v19.i8.1173] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 396 |
Li P, Cao G, Zhang Y, Shi J, Cai K, Zhen L, He X, Zhou Y, Li Y, Zhu Y, Xiong M, Wu Y. FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors. Aging (Albany NY) 2020;12:53-69. [PMID: 31935687 DOI: 10.18632/aging.102564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 397 |
Li X, Kamenecka TM, Cameron MD. Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos 2010;38:1238-45. [PMID: 20382753 DOI: 10.1124/dmd.109.030361] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 398 |
Kulkarni P, Haldar MK, You S, Choi Y, Mallik S. Hypoxia-Responsive Polymersomes for Drug Delivery to Hypoxic Pancreatic Cancer Cells. Biomacromolecules 2016;17:2507-13. [PMID: 27303825 DOI: 10.1021/acs.biomac.6b00350] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 399 |
Mita AC, Papadopoulos K, de Jonge MJ, Schwartz G, Verweij J, Mita MM, Ricart A, Chu QS, Tolcher AW, Wood L, McCarthy S, Hamilton M, Iwata K, Wacker B, Witt K, Rowinsky EK. Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer 2011;105:938-44. [PMID: 21878940 DOI: 10.1038/bjc.2011.332] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 400 |
Morgan MA, Meirovitz A, Davis MA, Kollar LE, Hassan MC, Lawrence TS. Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. Transl Oncol 2008;1:36-43. [PMID: 18607506 DOI: 10.1593/tlo.07106] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 401 |
Hindriksen S, Bijlsma MF. Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers (Basel) 2012;4:989-1035. [PMID: 24213498 DOI: 10.3390/cancers4040989] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 402 |
Carter CJ, Mekkawy AH, Morris DL. Role of human nucleoside transporters in pancreatic cancer and chemoresistance. World J Gastroenterol 2021; 27(40): 6844-6860 [PMID: 34790010 DOI: 10.3748/wjg.v27.i40.6844] [Reference Citation Analysis]
|
| 403 |
Wolfe AR, Williams TM. Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence. Ann Pancreat Cancer 2018;1:26. [PMID: 32656528 DOI: 10.21037/apc.2018.08.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 404 |
Adamska A, Falasca M. ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward? World J Gastroenterol 2018; 24(29): 3222-3238 [PMID: 30090003 DOI: 10.3748/wjg.v24.i29.3222] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 405 |
Schlick K, Kiem D, Greil R. Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature. Biomolecules 2021;11:1469. [PMID: 34680101 DOI: 10.3390/biom11101469] [Reference Citation Analysis]
|
| 406 |
Bhattacharjee V, Zhou Y, Yen TJ. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell Cycle 2014;13:3839-56. [PMID: 25558828 DOI: 10.4161/15384101.2014.967070] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 407 |
Kadera BE, Toste PA, Wu N, Li L, Nguyen AH, Dawson DW, Donahue TR. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. Clin Cancer Res. 2015;21:157-165. [PMID: 25348515 DOI: 10.1158/1078-0432.ccr-14-0610] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 408 |
Huang ZQ, Saluja AK, Dudeja V, Vickers SM, Buchsbaum DJ. Molecular targeted approaches for treatment of pancreatic cancer. Curr Pharm Des. 2011;17:2221-2238. [PMID: 21777178 DOI: 10.2174/138161211796957427] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 409 |
Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN. Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol 2012;30:3444-7. [PMID: 22927522 DOI: 10.1200/JCO.2012.41.9580] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 410 |
Höpfner M, Schuppan D, Scherübl H. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectives. World J Gastroenterol 2008; 14(16): 2461-2473 [PMID: 18442192 DOI: 10.3748/wjg.14.2461] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 411 |
Nakai Y, Isayama H, Sasaki T, Takahara N, Saito K, Ishigaki K, Hamada T, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D, Kogure H, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. J Cancer Res Clin Oncol 2015;141:933-9. [PMID: 25398651 DOI: 10.1007/s00432-014-1873-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 412 |
Venkatasubbarao K, Peterson L, Zhao S, Hill P, Cao L, Zhou Q, Nawrocki ST, Freeman JW. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Mol Cancer 2013;12:104. [PMID: 24025152 DOI: 10.1186/1476-4598-12-104] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 413 |
Wooten DJ, Sinha I, Sinha R. Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine. Biomedicines 2022;10:149. [DOI: 10.3390/biomedicines10010149] [Reference Citation Analysis]
|
| 414 |
Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016;22:61-68. [PMID: 26251290 DOI: 10.1158/1078-0432.ccr-15-0979] [Cited by in Crossref: 68] [Cited by in F6Publishing: 38] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 415 |
Paniccia A, Merkow J, Edil BH, Zhu Y. Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Chin J Cancer Res 2015;27:376-91. [PMID: 26361407 DOI: 10.3978/j.issn.1000-9604.2015.05.01] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
|
| 416 |
Walters DM, Lindberg JM, Adair SJ, Newhook TE, Cowan CR, Stokes JB, Borgman CA, Stelow EB, Lowrey BT, Chopivsky ME, Gilmer TM, Parsons JT, Bauer TW. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. Neoplasia 2013;15:143-55. [PMID: 23441129 DOI: 10.1593/neo.121712] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 417 |
Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30:355-385. [PMID: 26883357 DOI: 10.1101/gad.275776.115] [Cited by in Crossref: 241] [Cited by in F6Publishing: 226] [Article Influence: 40.2] [Reference Citation Analysis]
|
| 418 |
Tsai AC, Wang CY, Liou JP, Pai HC, Hsiao CJ, Chang JY, Wang JC, Teng CM, Pan SL. Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib. Cell Death Dis 2014;5:e1162. [PMID: 24722287 DOI: 10.1038/cddis.2014.128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 419 |
Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol 2019;26:4489-97. [PMID: 31418130 DOI: 10.1245/s10434-019-07685-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 420 |
Kiesewetter B, Raderer M, Prager GW, Fuereder T, Marosi C, Preusser M, Krainer M, Locker GJ, Brodowicz T, Zielinski CC. The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO Open 2017;2:e000166. [PMID: 28761758 DOI: 10.1136/esmoopen-2017-000166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 421 |
Nakai Y, Isayama H, Ijichi H, Sasaki T, Takahara N, Ito Y, Matsubara S, Uchino R, Yagioka H, Arizumi T, Hamada T, Miyabayashi K, Mizuno S, Yamamoto K, Kogure H, Yamamoto N, Hirano K, Sasahira N, Tateishi K, Tada M, Koike K. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Invest New Drugs 2013;31:1294-9. [PMID: 23690239 DOI: 10.1007/s10637-013-9972-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 422 |
Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y. Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med 2011;2:103-8. [PMID: 22977477 DOI: 10.3892/etm.2010.181] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 423 |
Lo JH, Hao L, Muzumdar MD, Raghavan S, Kwon EJ, Pulver EM, Hsu F, Aguirre AJ, Wolpin BM, Fuchs CS, Hahn WC, Jacks T, Bhatia SN. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther 2018;17:2377-88. [PMID: 30097486 DOI: 10.1158/1535-7163.MCT-17-1090] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 424 |
Sheahan AV, Biankin AV, Parish CR, Khachigian LM. Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget 2018;9:21613-27. [PMID: 29765563 DOI: 10.18632/oncotarget.25085] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 425 |
Thota R, Maitra A, Berlin JD. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Pancreas 2017;46:143-50. [PMID: 28085753 DOI: 10.1097/MPA.0000000000000753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 426 |
Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015;33:4284-4292. [PMID: 26527777 DOI: 10.1200/jco.2015.62.8719] [Cited by in Crossref: 266] [Cited by in F6Publishing: 172] [Article Influence: 38.0] [Reference Citation Analysis]
|
| 427 |
Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, Adjei AA. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol 2019;42:184-9. [PMID: 30418178 DOI: 10.1097/COC.0000000000000492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 428 |
Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010;10:130-7. [PMID: 20094047 DOI: 10.1038/nrc2787] [Cited by in Crossref: 508] [Cited by in F6Publishing: 470] [Article Influence: 42.3] [Reference Citation Analysis]
|
| 429 |
Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14:1455-1463. [PMID: 18316569 DOI: 10.1158/1078-0432.ccr-07-0371] [Cited by in Crossref: 225] [Cited by in F6Publishing: 152] [Article Influence: 16.1] [Reference Citation Analysis]
|
| 430 |
Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, Kim G, Fruehauf J, Imagawa DK, Hoffman RM, Katz MH. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther. 2010;9:2068-2078. [PMID: 20606044 DOI: 10.1158/1535-7163.mct-10-0201] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 431 |
Guo JC, Yang SH. Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study. Int J Clin Oncol 2014;19:634-42. [PMID: 24077663 DOI: 10.1007/s10147-013-0622-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 432 |
Montemagno C, Cassim S, De Leiris N, Durivault J, Faraggi M, Pagès G. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine? Int J Mol Sci 2021;22:6413. [PMID: 34203923 DOI: 10.3390/ijms22126413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 433 |
Ishizaki H, Manuel ER, Song GY, Srivastava T, Sun S, Diamond DJ, Ellenhorn JD. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother. 2011;60:99-109. [PMID: 20960189 DOI: 10.1007/s00262-010-0923-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 434 |
Kang BW, Chau I. Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. Expert Opin Investig Drugs 2021;:1-19. [PMID: 34727804 DOI: 10.1080/13543784.2021.1995354] [Reference Citation Analysis]
|
| 435 |
Yasui H, Sato K, Takeyama Y, Kato T, Hashimoto H, Fukui Y, Yoshihisa N, Maeda M, Gonda H, Suzuki R. Carcinoma of unknown primary site treated with Carboplatin + Paclitaxel + bevacizumab + erlotinib and its maintenance chemotherapy. Case Rep Oncol 2014;7:583-90. [PMID: 25298764 DOI: 10.1159/000366268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 436 |
Choi JG, Seo JH, Oh SC, Choi CW, Kim JS. A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. Cancer Res Treat. 2012;44:127-132. [PMID: 22802751 DOI: 10.4143/crt.2012.44.2.127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 437 |
Ko AH. Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer. Hepatobiliary Surg Nutr 2018;7:406-8. [PMID: 30498720 DOI: 10.21037/hbsn.2018.06.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 438 |
Peng X, Chen L, Jiao Y, Wang Y, Hao Z, Zhan X. Application of natural killer cells in pancreatic cancer. Oncol Lett 2021;22:647. [PMID: 34386069 DOI: 10.3892/ol.2021.12908] [Reference Citation Analysis]
|
| 439 |
Pappalardo A, Giunta EF, Tirino G, Pompella L, Federico P, Daniele B, De Vita F, Petrillo A. Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. Front Oncol 2021;11:695627. [PMID: 34485130 DOI: 10.3389/fonc.2021.695627] [Reference Citation Analysis]
|
| 440 |
Ji HB, Chen ZH. Clinical effects of stereotactic radiotherapy combined with gemcitabine in treatment of locally advanced pancreatic carcinoma. Shijie Huaren Xiaohua Zazhi 2015; 23(36): 5882-5888 [DOI: 10.11569/wcjd.v23.i36.5882] [Reference Citation Analysis]
|
| 441 |
Arias-Pinilla GA, Dalgleish AG, Mudan S, Bagwan I, Walker AJ, Modjtahedi H. Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer. Oncotarget 2018;9:19994-20007. [PMID: 29731998 DOI: 10.18632/oncotarget.25017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 442 |
Wang JP, Wu CY, Yeh YC, Shyr YM, Wu YY, Kuo CY, Hung YP, Chen MH, Lee WP, Luo JC, Chao Y, Li CP. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget. 2015;6:18162-18173. [PMID: 26046796 DOI: 10.18632/oncotarget.4216] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 443 |
Li D, O'Reilly EM. Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma. Semin Oncol 2015;42:134-43. [PMID: 25726058 DOI: 10.1053/j.seminoncol.2014.12.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 444 |
Kourie HR, Gharios J, Elkarak F, Antoun J, Ghosn M. Is metastatic pancreatic cancer an untargetable malignancy? World J Gastrointest Oncol 2016; 8(3): 297-304 [PMID: 26989465 DOI: 10.4251/wjgo.v8.i3.297] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 445 |
Freidlin B, Korn EL. Monitoring for lack of benefit: a critical component of a randomized clinical trial. J Clin Oncol 2009;27:629-33. [PMID: 19064977 DOI: 10.1200/JCO.2008.17.8905] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 446 |
Lellouche L, Palmieri LJ, Dermine S, Brezault C, Chaussade S, Coriat R. Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. Ther Adv Med Oncol 2021;13:17588359211018539. [PMID: 34285720 DOI: 10.1177/17588359211018539] [Reference Citation Analysis]
|
| 447 |
Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ. Interactions of everolimus and sorafenib in pancreatic cancer cells. AAPS J 2013;15:78-84. [PMID: 23054975 DOI: 10.1208/s12248-012-9417-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 448 |
Mo J, Lin M, He B, Tan K, Jin C, Jiang H, Pan X, Lin W. Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion. Oncol Lett 2017;14:6829-32. [PMID: 29181104 DOI: 10.3892/ol.2017.7058] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 449 |
Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol. 2014;74:379-387. [PMID: 24939212 DOI: 10.1007/s00280-014-2499-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 450 |
Watson RL, Spalding AC, Zielske SP, Morgan M, Kim AC, Bommer GT, Eldar-Finkelman H, Giordano T, Fearon ER, Hammer GD, Lawrence TS, Ben-Josef E. GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. Neoplasia 2010;12:357-65. [PMID: 20454507 DOI: 10.1593/neo.92112] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 451 |
Kordes M, Yu J, Malgerud O, Gustafsson Liljefors M, Löhr J-. Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort. Cancers (Basel) 2019;11:E1326. [PMID: 31500236 DOI: 10.3390/cancers11091326] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 452 |
Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G, Georgoulias V. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer. 2006;95:587-592. [PMID: 16909140 DOI: 10.1038/sj.bjc.6603301] [Cited by in Crossref: 140] [Cited by in F6Publishing: 145] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 453 |
Wang T, Zhuang Z, Zhang P, Wang Y, Mu L, Jin H, Zhou L, Ma X, Liang R, Yuan Y. Effect of arenobufagin on human pancreatic carcinoma cells. Oncol Lett 2017;14:4971-6. [PMID: 29085509 DOI: 10.3892/ol.2017.6798] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 454 |
Bupathi M, Ahn DH, Wu C, Ciombor KK, Stephens JA, Reardon J, Goldstein DA, Bekaii-Saab T. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Med Oncol 2016;33:37. [PMID: 26995224 DOI: 10.1007/s12032-016-0753-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 455 |
Strauss J, Alewine C, Figg WD, Duffy A. Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. Clin Transl Oncol 2016;18:653-9. [PMID: 26661112 DOI: 10.1007/s12094-015-1459-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 456 |
Eltawil KM, Renfrew PD, Molinari M. Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. HPB (Oxford) 2012;14:260-8. [PMID: 22404265 DOI: 10.1111/j.1477-2574.2012.00441.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 457 |
Hartwig W, Büchler MW. Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. Gastrointest Tumors 2013;1:41-52. [PMID: 26673950 DOI: 10.1159/000354992] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 458 |
Enewold L, Harlan LC, Tucker T, McKenzie S. Pancreatic cancer in the USA: persistence of undertreatment and poor outcome. J Gastrointest Cancer 2015;46:9-20. [PMID: 25403828 DOI: 10.1007/s12029-014-9668-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 459 |
Sirohi B, Singh A, Dawood S, Shrikhande SV. Advances in chemotherapy for pancreatic cancer. Indian J Surg Oncol 2015;6:47-56. [PMID: 25937764 DOI: 10.1007/s13193-014-0371-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 460 |
Wu CP, Murakami M, Wu YS, Chi YC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV. Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. Front Cell Dev Biol 2021;9:699571. [PMID: 34350184 DOI: 10.3389/fcell.2021.699571] [Reference Citation Analysis]
|
| 461 |
Chazova IE, Oshchepkova EV, Kantorova AY. [Comorbidity of cardiovascular diseases and cancers: Problems in the diagnosis of cardiotoxic effects of chemo- and radiation therapy]. Ter Arkh 2015;87:4-10. [PMID: 26591546 DOI: 10.17116/terarkh20158794-10] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 462 |
Isacoff WH, Reber HA, Bedford R, Hoos W, Rahib L, Upfill-Brown A, Donahue T, Hines OJ. Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. Target Oncol 2018;13:461-8. [PMID: 29882102 DOI: 10.1007/s11523-018-0572-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 463 |
Hwang IG, Jang JS, Oh SY, Lee S, Kwon HC, Lee GW, Go S, Kang MH, Cha YJ, Kang JH. A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. Invest New Drugs 2012;30:2371-6. [PMID: 22302349 DOI: 10.1007/s10637-012-9792-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 464 |
Pook H, Pauklin S. Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:4834. [PMID: 34638318 DOI: 10.3390/cancers13194834] [Reference Citation Analysis]
|
| 465 |
Wu C, Fernandez SA, Criswell T, Chidiac TA, Guttridge D, Villalona-Calero M, Bekaii-Saab TS. Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas. 2013;42:813-818. [PMID: 23429495 DOI: 10.1097/mpa.0b013e318279b87f] [Cited by in Crossref: 44] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 466 |
Hong RA, Iimura T, Sumida KN, Eager RM. Cardio-oncology/onco-cardiology. Clin Cardiol 2010;33:733-7. [PMID: 21184556 DOI: 10.1002/clc.20823] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 467 |
Kotasek D, Tebbutt N, Desai J, Welch S, Siu LL, McCoy S, Sun YN, Johnson J, Adewoye AH, Price T. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer 2011;11:313. [PMID: 21791058 DOI: 10.1186/1471-2407-11-313] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 468 |
He X, Sun Y, Fan R, Sun J, Zou D, Yuan Y. Knockdown of the DJ-1 (PARK7) gene sensitizes pancreatic cancer to erlotinib inhibition. Mol Ther Oncolytics 2021;20:364-72. [PMID: 33614917 DOI: 10.1016/j.omto.2021.01.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 469 |
Ioannou N, Seddon AM, Dalgleish A, Mackintosh D, Solca F, Modjtahedi H. Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. Int J Oncol 2016;48:908-18. [PMID: 26781210 DOI: 10.3892/ijo.2016.3320] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 470 |
Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012;4:127ps8. [PMID: 22461638 DOI: 10.1126/scitranslmed.3003634] [Cited by in Crossref: 168] [Cited by in F6Publishing: 153] [Article Influence: 16.8] [Reference Citation Analysis]
|
| 471 |
Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27:193-198. [PMID: 19047305 DOI: 10.1200/jco.2008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 472 |
Gerhart J, Thévenin AF, Bloch E, King KE, Thévenin D. Inhibiting Epidermal Growth Factor Receptor Dimerization and Signaling Through Targeted Delivery of a Juxtamembrane Domain Peptide Mimic. ACS Chem Biol 2018;13:2623-32. [PMID: 30133245 DOI: 10.1021/acschembio.8b00555] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 473 |
Farrell AS, Allen-Petersen B, Daniel CJ, Wang X, Wang Z, Rodriguez S, Impey S, Oddo J, Vitek MP, Lopez C, Christensen DJ, Sheppard B, Sears RC. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. Mol Cancer Res 2014;12:924-39. [PMID: 24667985 DOI: 10.1158/1541-7786.MCR-13-0542] [Cited by in Crossref: 66] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 474 |
Suzuki N, Hazama S, Iguchi H, Uesugi K, Tanaka H, Hirakawa K, Aruga A, Hatori T, Ishizaki H, Umeda Y, Fujiwara T, Ikemoto T, Shimada M, Yoshimatsu K, Shimizu R, Hayashi H, Sakata K, Takenouchi H, Matsui H, Shindo Y, Iida M, Koki Y, Arima H, Furukawa H, Ueno T, Yoshino S, Nakamura Y, Oka M, Nagano H. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci 2017;108:73-80. [PMID: 27783849 DOI: 10.1111/cas.13113] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 475 |
Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 2020;77:1745-70. [PMID: 31690961 DOI: 10.1007/s00018-019-03351-7] [Cited by in Crossref: 157] [Cited by in F6Publishing: 151] [Article Influence: 52.3] [Reference Citation Analysis]
|
| 476 |
Chawla A, Ferrone CR. Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. Front Oncol 2019;9:1085. [PMID: 31681614 DOI: 10.3389/fonc.2019.01085] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 477 |
Kim H, Samuel S, Lopez-Casas P, Grizzle W, Hidalgo M, Kovar J, Oelschlager D, Zinn K, Warram J, Buchsbaum D. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Mol Cancer Ther. 2016;15:680-688. [PMID: 26832793 DOI: 10.1158/1535-7163.mct-15-0764] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 478 |
Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer 2013;21:1167-74. [PMID: 23151647 DOI: 10.1007/s00520-012-1645-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 479 |
Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE 2nd, Coan A, McSherry F, Rich JN, McLendon RE, Zhang S, Friedman HS. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neurooncol 2012;108:499-506. [PMID: 22407177 DOI: 10.1007/s11060-012-0848-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 480 |
Gilles ME, Hao L, Brown K, Lim J, Bhatia SN, Slack FJ. Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer. Oncotarget 2019;10:5349-58. [PMID: 31523393 DOI: 10.18632/oncotarget.27160] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 481 |
Kosmidis C, Sapalidis K, Kotidis E, Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG, Kanellos J. Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med 2016;4:165. [PMID: 27275478 DOI: 10.21037/atm.2016.05.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 482 |
Nishimura M, Hayashi M, Mizutani Y, Takenaka K, Imamura Y, Chayahara N, Toyoda M, Kiyota N, Mukohara T, Aikawa H, Fujiwara Y, Hamada A, Minami H. Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. Oncotarget 2018;9:18540-7. [PMID: 29719624 DOI: 10.18632/oncotarget.24928] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 483 |
Wei WT, Chen H, Wang ZH, Ni ZL, Liu HB, Tong HF, Guo HC, Liu DL, Lin SZ. Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. Int J Biol Sci 2012;8:1-14. [PMID: 22211100 DOI: 10.7150/ijbs.8.1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 484 |
D'Onofrio M, Crosara S, De Robertis R, Butturini G, Salvia R, Paiella S, Bassi C, Mucelli RP. Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results. Technol Cancer Res Treat. 2017;16:285-294. [PMID: 27193941 DOI: 10.1177/1533034616649292] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 485 |
Muñoz AR, Chakravarthy D, Gong J, Halff GA, Ghosh R, Kumar AP. Pancreatic cancer: Current status and Challenges. Curr Pharmacol Rep 2017;3:396-408. [PMID: 29404265 DOI: 10.1007/s40495-017-0112-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 486 |
Sakaguchi T, Satoi S, Yamamoto T, Yamaki S, Sekimoto M. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. Surg Today 2020;50:335-43. [PMID: 31993761 DOI: 10.1007/s00595-020-01963-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 487 |
Shultz DB, Pai J, Chiu W, Ng K, Hellendag MG, Heestand G, Chang DT, Tu D, Moore MJ, Parulekar WR, Koong AC. A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. PLoS One 2016;11:e0147995. [PMID: 26808546 DOI: 10.1371/journal.pone.0147995] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 488 |
Martín AM, Hidalgo M, Alvarez R, Arrazubi V, Martínez-Galán J, Salgado M, Macarulla T, Carrato A. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. J Cancer 2018;9:1978-88. [PMID: 29896283 DOI: 10.7150/jca.23716] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 489 |
Jing W, Song N, Liu Y, Qu X, Hou K, Yang X, Che X. DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53‑deficient pancreatic cancer cells. Mol Med Rep 2018;17:117-24. [PMID: 29115606 DOI: 10.3892/mmr.2017.7923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 490 |
Damanakis AI, Gebauer F, Bruns CJ. [Molecular predictors for the course of disease and individualized therapy in pancreatic cancer]. Chirurg 2020;91:642-9. [PMID: 32405728 DOI: 10.1007/s00104-020-01172-0] [Reference Citation Analysis]
|
| 491 |
Mancinelli G, Torres C, Krett N, Bauer J, Castellanos K, McKinney R, Dawson D, Guzman G, Hwang R, Grimaldo S, Grippo P, Jung B. Role of stromal activin A in human pancreatic cancer and metastasis in mice. Sci Rep 2021;11:7986. [PMID: 33846512 DOI: 10.1038/s41598-021-87213-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 492 |
Cherri S, Noventa S, Zaniboni A. Pancreatic adenocarcinoma: Beyond first line, where are we? World J Gastroenterol 2021; 27(17): 1847-1863 [PMID: 34007126 DOI: 10.3748/wjg.v27.i17.1847] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 493 |
Logsdon CD, Abbruzzese JL. Chemoprevention of pancreatic cancer: ready for the clinic? Cancer Prev Res (Phila) 2010;3:1375-8. [PMID: 21084259 DOI: 10.1158/1940-6207.CAPR-10-0216] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 494 |
Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D. Pancreatic cancer in young adults: changes, challenges, and solutions. Onco Targets Ther 2019;12:3387-400. [PMID: 31118690 DOI: 10.2147/OTT.S176700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 495 |
Ghosn M, Kourie HR, Karak FE, Hanna C, Antoun J, Nasr D. Optimum chemotherapy in the management of metastatic pancreatic cancer. World J Gastroenterol 2014; 20(9): 2352-2357 [PMID: 24605032 DOI: 10.3748/wjg.v20.i9.2352] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 496 |
Tabernero J, Kunzmann V, Scheithauer W, Reni M, Shiansong Li J, Ferrara S, Djazouli K. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. Onco Targets Ther 2017;10:591-6. [PMID: 28203092 DOI: 10.2147/OTT.S124097] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 497 |
Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, Hendlisz A, Van Laethem JL. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006;94:481-5. [PMID: 16434988 DOI: 10.1038/sj.bjc.6602966] [Cited by in Crossref: 84] [Cited by in F6Publishing: 85] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 498 |
Dittrich C, Königsberg R, Mittlböck M, Geissler K, Sahmanovic-Hrgovcic A, Pleiner-Duxneuner J, Czejka M, Buchner P. Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial. Invest New Drugs 2019;37:127-38. [PMID: 29998365 DOI: 10.1007/s10637-018-0639-0] [Reference Citation Analysis]
|
| 499 |
O’Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010;15:1310-1319. [PMID: 21148613 DOI: 10.1634/theoncologist.2010-0152] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 500 |
Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol 2011;5:89-99. [PMID: 21603244 DOI: 10.4137/CMO.S6983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 501 |
Nikolaou C, Matikas A, Papavasilopoulou M, Mavroudis D, Vamvakas L. Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI. Case Rep Oncol Med 2015;2015:659624. [PMID: 26090249 DOI: 10.1155/2015/659624] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 502 |
Ubezio P, Falcetta F, Carrassa L, Lupi M. Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer. Oncotarget 2016;7:15492-506. [PMID: 26909860 DOI: 10.18632/oncotarget.7491] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 503 |
Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418-429. [PMID: 22439937 DOI: 10.1016/j.ccr.2012.01.007] [Cited by in Crossref: 1156] [Cited by in F6Publishing: 1136] [Article Influence: 115.6] [Reference Citation Analysis]
|
| 504 |
Zhao YD, Yang JK, Zhao AG. Advances in medical treatment of advanced pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2012; 20(25): 2370-2376 [DOI: 10.11569/wcjd.v20.i25.2370] [Reference Citation Analysis]
|
| 505 |
Roberts AS, Campa MJ, Gottlin EB, Jiang C, Owzar K, Kindler HL, Venook AP, Goldberg RM, O'Reilly EM, Patz EF Jr. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer 2012;118:571-8. [PMID: 21713765 DOI: 10.1002/cncr.26270] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 506 |
Chen J, Kaley K, Garcon MC, Rodriguez T, Saif MW. A novel schedule of erlotinib/capecitabine (7/7) as salvage therapy in previously treated advanced pancreatic adenocarcinoma: a case series. Therap Adv Gastroenterol 2016;9:162-8. [PMID: 26929778 DOI: 10.1177/1756283X15622779] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 507 |
Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium--the just price. J Clin Oncol 2013;31:3600-4. [PMID: 23650428 DOI: 10.1200/JCO.2013.49.1845] [Cited by in Crossref: 215] [Cited by in F6Publishing: 77] [Article Influence: 23.9] [Reference Citation Analysis]
|
| 508 |
Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M, Kent E, Bown SG, Hasan T, Pogue BW. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014;110:1698-1704. [PMID: 24569464 DOI: 10.1038/bjc.2014.95] [Cited by in Crossref: 178] [Cited by in F6Publishing: 173] [Article Influence: 22.3] [Reference Citation Analysis]
|
| 509 |
Peng Z, Ji Z, Mei F, Lu M, Ou Y, Cheng X. Lithium inhibits tumorigenic potential of PDA cells through targeting hedgehog-GLI signaling pathway. PLoS One. 2013;8:e61457. [PMID: 23626687 DOI: 10.1371/journal.pone.0061457] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 510 |
Chiu JW, Wong H, Leung R, Pang R, Cheung TT, Fan ST, Poon R, Yau T. Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist 2014;19:937-50. [PMID: 25117068 DOI: 10.1634/theoncologist.2012-0131] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 511 |
Tada M, Nakai Y, Sasaki T, Hamada T, Nagano R, Mohri D, Miyabayashi K, Yamamoto K, Kogure H, Kawakubo K, Ito Y, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Isayama H, Omata M, Koike K. Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World J Clin Oncol 2011; 2(3): 158-163 [PMID: 21611090 DOI: 10.5306/wjco.v2.i3.158] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 512 |
Yuan K, Sun Y, Zhou T, McDonald J, Chen Y. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy. Clin Cancer Res 2013;19:4750-9. [PMID: 23833311 DOI: 10.1158/1078-0432.CCR-13-0516] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 513 |
Lin H, Hu C, Zheng S, Zhang X, Chen R, Zhou Q. A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer. Aging (Albany NY) 2021;13:12493-513. [PMID: 33901011 DOI: 10.18632/aging.202922] [Reference Citation Analysis]
|
| 514 |
Abrams MJ, Rakszawski K, Vasekar M, Passero F, Abbas A, Jia Y, Saif MW. Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. Therap Adv Gastroenterol 2016;9:141-51. [PMID: 26929776 DOI: 10.1177/1756283X15622601] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 515 |
Manegold P, Lai KKY, Wu Y, Teo JL, Lenz HJ, Genyk YS, Pandol SJ, Wu K, Lin DP, Chen Y, Nguyen C, Zhao Y, Kahn M. Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer. Cancers (Basel) 2018;10:E95. [PMID: 29596326 DOI: 10.3390/cancers10040095] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 516 |
Yang HH, Liu JW, Lee JH, Harn HJ, Chiou TW. Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor. Int J Mol Sci 2021;22:8125. [PMID: 34360896 DOI: 10.3390/ijms22158125] [Reference Citation Analysis]
|
| 517 |
Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Toda N, Kogure H, Matsubara S, Ito Y, Togawa O, Arizumi T, Hirano K, Tada M, Omata M, Koike K. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer 2012;106:1934-9. [PMID: 22555398 DOI: 10.1038/bjc.2012.183] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 518 |
Niccolai E, Prisco D, D’Elios MM, Amedei A. What is recent in pancreatic cancer immunotherapy? Biomed Res Int. 2013;492372. [PMID: 23509731 DOI: 10.1155/2013/492372] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 519 |
Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA; NCCN Pancreatic Adenocarcinoma. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010;8:972-1017. [PMID: 20876541 DOI: 10.6004/jnccn.2010.0073] [Cited by in Crossref: 122] [Cited by in F6Publishing: 111] [Article Influence: 10.2] [Reference Citation Analysis]
|
| 520 |
Okusaka T, Furuse J. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020;55:369-382. [PMID: 31997007 DOI: 10.1007/s00535-020-01666-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 521 |
Reese M, Dhayat SA. Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications. J Hematol Oncol 2021;14:141. [PMID: 34496946 DOI: 10.1186/s13045-021-01149-4] [Reference Citation Analysis]
|
| 522 |
Socoteanu MP, Mott F, Alpini G, Frankel AE. c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol 2008; 14(19): 2990-2994 [PMID: 18494048 DOI: 10.3748/wjg.14.2990] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 523 |
Vasey PA, Gore M, Wilson R, Rustin G, Gabra H, Guastalla JP, Lauraine EP, Paul J, Carty K, Kaye S; Scottish Gynaecological Cancer Trials Group. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer 2008;98:1774-80. [PMID: 18506181 DOI: 10.1038/sj.bjc.6604371] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 524 |
Rao CV, Janakiram NB, Madka V, Devarkonda V, Brewer M, Biddick L, Lightfoot S, Steele VE, Mohammed A. Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Oncotarget 2015;6:33290-305. [PMID: 26429877 DOI: 10.18632/oncotarget.5396] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 525 |
Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov 2020;19:533-52. [PMID: 32528145 DOI: 10.1038/s41573-020-0068-6] [Cited by in Crossref: 108] [Cited by in F6Publishing: 110] [Article Influence: 54.0] [Reference Citation Analysis]
|
| 526 |
Häberle L, Braren R, Schlitter AM, Esposito I. [Metastasis of pancreatic tumors]. Pathologe 2015;36 Suppl 2:176-80. [PMID: 26391249 DOI: 10.1007/s00292-015-0077-0] [Reference Citation Analysis]
|
| 527 |
Kim J, Jo YH, Jang M, Nguyen NNY, Yun HR, Ko SH, Shin Y, Lee JS, Kang I, Ha J, Choi TG, Kim SS. PAC-5 Gene Expression Signature for Predicting Prognosis of Patients with Pancreatic Adenocarcinoma. Cancers (Basel) 2019;11:E1749. [PMID: 31703415 DOI: 10.3390/cancers11111749] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 528 |
Weickhardt A, Michael M. Pancreatic cancer: advances in medical therapy. Expert Rev Clin Pharmacol 2009;2:173-80. [PMID: 24410649 DOI: 10.1586/17512433.2.2.173] [Reference Citation Analysis]
|
| 529 |
Bedi D, Gillespie JW, Petrenko VA. Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines. Protein Eng Des Sel 2014;27:235-43. [PMID: 24899628 DOI: 10.1093/protein/gzu020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 530 |
Liu HL, Wang L. Advances in the early diagnosis and therapy of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2009; 17(34): 3475-3479 [DOI: 10.11569/wcjd.v17.i34.3475] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 531 |
Duckett DR, Cameron MD. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol 2010;6:1175-93. [PMID: 20684746 DOI: 10.1517/17425255.2010.506873] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 532 |
Yoshizawa N, Yamada R, Sakuno T, Inoue H, Miura H, Takeuchi T, Nakamura M, Hamada Y, Katsurahara M, Tanaka K, Horiki N, Takei Y. Comparison of endoscopic ultrasound-guided fine-needle aspiration and biopsy with 22-gauge and 25-gauge needles for the "precision medicine" of pancreatic cancer: A retrospective study. Medicine (Baltimore) 2018;97:e11096. [PMID: 29901627 DOI: 10.1097/MD.0000000000011096] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 533 |
Ueda A, Hosokawa A, Ogawa K, Yoshita H, Ando T, Kajiura S, Fujinami H, Kawai K, Nishikawa J, Tajiri K, Minemura M, Sugiyama T. Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial. Onco Targets Ther 2013;6:491-6. [PMID: 23690691 DOI: 10.2147/OTT.S43287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 534 |
Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W, Tonghua L. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 2009;8:125. [PMID: 20021699 DOI: 10.1186/1476-4598-8-125] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 535 |
Kim ST, Jang KT, Lee J, Jang HM, Choi HJ, Jang HL, Park SH, Park YS, Lim HY, Kang WK, Park JO. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. Transl Oncol 2015;8:40-6. [PMID: 25749176 DOI: 10.1016/j.tranon.2014.12.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 536 |
Ali R, Wendt MK. The paradoxical functions of EGFR during breast cancer progression. Signal Transduct Target Ther 2017;2:16042. [PMID: 28435746 DOI: 10.1038/sigtrans.2016.42] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 537 |
Vilallonga R, Sanchez JL, Armengol M. Gastrointestinal Stromal Tumor: Cause of Gastrointestinal Bleeding. Gastroenterology Res 2010;3:93-5. [PMID: 27956992 DOI: 10.4021/gr2010.03.178w] [Reference Citation Analysis]
|
| 538 |
Blaszak M, El-Masri M, Hirmiz K, Mathews J, Omar A, Elfiki T, Gupta R, Hamm C, Kanjeekal S, Kay A, Kulkarni S, Ghafoor A. Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study. Mol Clin Oncol 2017;6:583-8. [PMID: 28413673 DOI: 10.3892/mco.2017.1179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 539 |
Okusaka T, Miyakawa H, Fujii H, Nakamori S, Satoh T, Hamamoto Y, Ito T, Maguchi H, Matsumoto S, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Chen JS, Cheng AL, Sato A, Ohashi Y, Tanaka M; GEST group. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. J Cancer Res Clin Oncol 2017;143:1053-9. [PMID: 28210843 DOI: 10.1007/s00432-017-2349-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 540 |
Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828-833. [PMID: 20842054 DOI: 10.1097/cji.0b013eec14c] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 541 |
Liu L, Wang E, Li L, Chen D, Peng K, Wang M, Han G. As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib. Can J Gastroenterol Hepatol 2019;2019:2576349. [PMID: 31815114 DOI: 10.1155/2019/2576349] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 542 |
Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen WP, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, Rodriguez LM, Szabo E, Rosenberg DW, Lipkin SM. A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum. Cancer Prev Res (Phila) 2015;8:222-30. [PMID: 25604134 DOI: 10.1158/1940-6207.CAPR-14-0148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 543 |
Iovanna J, Mallmann MC, Gonçalves A, Turrini O, Dagorn JC. Current knowledge on pancreatic cancer. Front Oncol. 2012;2:6. [PMID: 22655256 DOI: 10.3389/fonc.2012.00006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 544 |
Masu T, Atsukawa M, Nakatsuka K, Shimizu M, Miura D, Arai T, Harimoto H, Kondo C, Kaneko K, Futagami S, Kawamoto C, Takahashi H, Iwakiri K. Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression. PLoS One 2018;13:e0200664. [PMID: 30596643 DOI: 10.1371/journal.pone.0200664] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 545 |
Hafeez BB, Mustafa A, Fischer JW, Singh A, Zhong W, Shekhani MO, Meske L, Havighurst T, Kim K, Verma AK. α-Mangostin: a dietary antioxidant derived from the pericarp of Garcinia mangostana L. inhibits pancreatic tumor growth in xenograft mouse model. Antioxid Redox Signal 2014;21:682-99. [PMID: 24295217 DOI: 10.1089/ars.2013.5212] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 546 |
Lim CS, Lee YG, Koh Y, Heo DS. International comparison of the factors influencing reimbursement of targeted anti-cancer drugs. BMC Health Serv Res 2014;14:595. [PMID: 25432511 DOI: 10.1186/s12913-014-0595-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 547 |
Yegya-Raman N, Shah MM, Grandhi MS, Poplin E, August DA, Kennedy TJ, Malhotra U, Spencer KR, Carpizo DR, Jabbour SK. Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Ann Pancreat Cancer 2018;1:20. [PMID: 30687847 DOI: 10.21037/apc.2018.07.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 548 |
De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2012;69:415-424. [PMID: 21800112 DOI: 10.1007/s00280-011-1704-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 549 |
Liu F, Tang Y, Sun J, Yuan Z, Li S, Sheng J, Ren H, Hao J. Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2012;7:e40847. [PMID: 22815840 DOI: 10.1371/journal.pone.0040847] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 550 |
Goldstein DA, Krishna K, Flowers CR, El-Rayes BF, Bekaii-Saab T, Noonan AM. Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. Med Oncol. 2016;33:48. [PMID: 27067436 DOI: 10.1007/s12032-016-0762-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 551 |
Samuel N, Hudson TJ. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;9:77-87. [PMID: 22183185 DOI: 10.1038/nrgastro.2011.215] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 552 |
Delitto D, Pham K, Vlada AC, Sarosi GA, Thomas RM, Behrns KE, Liu C, Hughes SJ, Wallet SM, Trevino JG. Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. Am J Pathol 2015;185:1297-303. [PMID: 25770474 DOI: 10.1016/j.ajpath.2015.01.016] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 553 |
Sultana A, Shore S, Raraty MG, Vinjamuri S, Evans JE, Smith CT, Lane S, Chauhan S, Bosonnet L, Garvey C, Sutton R, Neoptolemos JP, Ghaneh P. Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer 2009;9:66. [PMID: 19243606 DOI: 10.1186/1471-2407-9-66] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 554 |
Thillai K, Sarker D, Ross P. Progress in pancreatic cancer therapeutics: The potential to exploit molecular targets. World J Pharmacol 2015; 4(2): 180-192 [DOI: 10.5497/wjp.v4.i2.180] [Reference Citation Analysis]
|
| 555 |
Zong Y, Peng Z, Wang X, Lu M, Shen L, Zhou J. Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma. Cancer Manag Res 2020;12:12657-66. [PMID: 33328763 DOI: 10.2147/CMAR.S263773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 556 |
Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500-503. [PMID: 21460848 DOI: 10.1038/nm.2344.subtypes] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 557 |
Abendroth A, Noureddine R, Abramczyk M, Paul A, Gerken G, Schmid KW, Markus P, Schumacher B, Wiesweg M, Köhler J, Markus M, Mende B, Dechêne A, Schuler M, Kasper S. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. J Cancer Res Clin Oncol 2019;145:445-55. [PMID: 30430229 DOI: 10.1007/s00432-018-2789-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 558 |
Koujima T, Tazawa H, Ieda T, Araki H, Fushimi T, Shoji R, Kuroda S, Kikuchi S, Yoshida R, Umeda Y, Teraishi F, Urata Y, Mizuguchi H, Fujiwara T. Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. Mol Ther Oncolytics 2020;17:107-17. [PMID: 32322667 DOI: 10.1016/j.omto.2020.03.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 559 |
McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, Bekaii-Saab T, Hung MC, Erlichman C, Fernandez-Zapico ME. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.Pancreatology. 2020;20:101-109. [PMID: 31787526 DOI: 10.1016/j.pan.2019.11.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 560 |
Chen Y, Hao J, Ma W, Tang Y, Gao C, Hao X. Improvement in treatment and outcome of pancreatic ductal adenocarcinoma in north China. J Gastrointest Surg. 2011;15:1026-1034. [PMID: 21484493 DOI: 10.1007/s11605-011-1493-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 561 |
Hedegger K, Algül H, Lesina M, Blutke A, Schmid RM, Schneider MR, Dahlhoff M. Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice. Mol Oncol 2020;14:1653-69. [PMID: 32335999 DOI: 10.1002/1878-0261.12699] [Reference Citation Analysis]
|
| 562 |
Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010;10:241-253. [PMID: 20300105 DOI: 10.1038/nrc2820] [Cited by in Crossref: 368] [Cited by in F6Publishing: 320] [Article Influence: 30.7] [Reference Citation Analysis]
|
| 563 |
Kirtane AR, Kalscheuer SM, Panyam J. Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev 2013;65:1731-47. [PMID: 24036273 DOI: 10.1016/j.addr.2013.09.001] [Cited by in Crossref: 163] [Cited by in F6Publishing: 157] [Article Influence: 18.1] [Reference Citation Analysis]
|
| 564 |
Azar I, Virk G, Esfandiarifard S, Wazir A, Mehdi S. Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study. J Gastrointest Oncol 2019;10:703-11. [PMID: 31392051 DOI: 10.21037/jgo.2018.07.08] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 565 |
Awasthi N, Zhang C, Schwarz AM, Hinz S, Schwarz MA, Schwarz RE. Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer. Mol Cancer Ther 2014;13:1032-43. [PMID: 24608575 DOI: 10.1158/1535-7163.MCT-13-0361] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 566 |
Wang Y, Kuramitsu Y, Tokuda K, Baron B, Kitagawa T, Akada J, Maehara S, Maehara Y, Nakamura K. Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer. PLoS One 2014;9:e109076. [PMID: 25271986 DOI: 10.1371/journal.pone.0109076] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 567 |
Herreros-Villanueva M, Rodrigo M, Claver M, Muñiz P, Lastra E, García-Girón C, Coma del Corral MJ. KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep 2011;38:1315-20. [PMID: 20563851 DOI: 10.1007/s11033-010-0232-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 568 |
Sasahara YI, Narimatsu H, Suzuki S, Fukui T, Sato H, Shirahata N, Yoshioka T. Personalization of chemotherapy for metastatic pancreatic cancer. Clin Med Insights Case Rep 2014;7:59-61. [PMID: 25093005 DOI: 10.4137/CCRep.S14478] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 569 |
Hammam K, Saez-Ayala M, Rebuffet E, Gros L, Lopez S, Hajem B, Humbert M, Baudelet E, Audebert S, Betzi S, Lugari A, Combes S, Letard S, Casteran N, Mansfield C, Moussy A, De Sepulveda P, Morelli X, Dubreuil P. Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology. Nat Commun 2017;8:1420. [PMID: 29127277 DOI: 10.1038/s41467-017-01582-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 570 |
Satoi S, Yanagimoto H, Yamamoto T, Toyokawa H, Hirooka S, Yamaki S, Opendro SS, Inoue K, Michiura T, Ryota H, Matsui Y, Kon M. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. World J Surg Oncol 2016;14:14. [PMID: 26791083 DOI: 10.1186/s12957-016-0767-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 571 |
Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep. 2018;8:8666. [PMID: 29875415 DOI: 10.1038/s41598-018-26811-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 572 |
Wykosky J, Fenton T, Furnari F, Cavenee WK. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin J Cancer 2011;30:5-12. [PMID: 21192840 DOI: 10.5732/cjc.010.10542] [Cited by in Crossref: 66] [Cited by in F6Publishing: 73] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 573 |
Starling N, Neoptolemos J, Cunningham D. Role of erlotinib in the management of pancreatic cancer. Ther Clin Risk Manag 2006;2:435-45. [PMID: 18360654 DOI: 10.2147/tcrm.2006.2.4.435] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 574 |
Guarino MJ, Schneider CJ, Hosford MA, Brahmer JR, Rudin CM, Finckenstein FG, Philip-Norton RE, Lu H, Weber MR, Ettinger DS. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist 2009;14:119-24. [PMID: 19182243 DOI: 10.1634/theoncologist.2008-0124] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 575 |
Herman JM, Fan KY, Wild AT, Hacker-Prietz A, Wood LD, Blackford AL, Ellsworth S, Zheng L, Le DT, De Jesus-Acosta A. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013;86:678-685. [PMID: 23773391 DOI: 10.1016/j.ijrobp.2013.03.032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 576 |
Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82. [PMID: 18373843 DOI: 10.1186/1471-2407-8-82] [Cited by in Crossref: 280] [Cited by in F6Publishing: 265] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 577 |
Sharma N, Bhushan A, He J, Kaushal G, Bhardwaj V. Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase. Cancer Metab 2020;8:19. [PMID: 32974013 DOI: 10.1186/s40170-020-00226-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 578 |
Walsh N, Kennedy S, Larkin A, Corkery B, O’Driscoll L, Clynes M, Crown J, O’Donovan N. EGFR and HER2 inhibition in pancreatic cancer. Invest New Drugs. 2013;31:558-566. [PMID: 23076814 DOI: 10.1007/s10637-012-9891-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 579 |
Zhao S, Cao L, Freeman JW. Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines. Oncogenesis 2013;2:e76. [PMID: 24100611 DOI: 10.1038/oncsis.2013.36] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 580 |
Simon N, FitzGerald D. Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers. Toxins (Basel) 2016;8:E137. [PMID: 27153091 DOI: 10.3390/toxins8050137] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 581 |
Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG. Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer 2016;7:1328-39. [PMID: 27390608 DOI: 10.7150/jca.15419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 582 |
Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics 2008;2:83-95. [PMID: 19707431 DOI: 10.2147/btt.s1832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 31] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 583 |
Denlinger CS, Cohen SJ. Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. Curr Treat Options Oncol 2007;8:339-51. [PMID: 18193357 DOI: 10.1007/s11864-007-0045-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 584 |
O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol 2015;26:1923-9. [PMID: 26091808 DOI: 10.1093/annonc/mdv264] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 585 |
Prevo R, Fokas E, Reaper PM, Charlton PA, Pollard JR, McKenna WG, Muschel RJ, Brunner TB. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther. 2012;13:1072-1081. [PMID: 22825331 DOI: 10.4161/cbt.21093] [Cited by in Crossref: 166] [Cited by in F6Publishing: 147] [Article Influence: 16.6] [Reference Citation Analysis]
|
| 586 |
Arias-Pinilla GA, Modjtahedi H. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers (Basel) 2021;13:1781. [PMID: 33917882 DOI: 10.3390/cancers13081781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 587 |
Sjoquist KM, Chin VT, Chantrill LA, O’Connor C, Hemmings C, Chang DK, Chou A, Pajic M, Johns AL, Nagrial AM, Biankin AV, Yip D. Personalising pancreas cancer treatment: When tissue is the issue. World J Gastroenterol 2014; 20(24): 7849-7863 [PMID: 24976722 DOI: 10.3748/wjg.v20.i24.7849] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 588 |
Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Ann Oncol. 2015;26:1194-1200. [PMID: 25858497 DOI: 10.1093/annonc/mdv133] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 589 |
Klaiber U, Leonhardt C, Strobel O, Tjaden C, Hackert T, Neoptolemos JP. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbecks Arch Surg 2018;403:917-32. [DOI: 10.1007/s00423-018-1724-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 590 |
Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouché O, Ychou M, Bensadoun RJ, Dreno B, André T. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist 2012;17:555-68. [PMID: 22426526 DOI: 10.1634/theoncologist.2011-0365] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 591 |
Jeong W, Doroshow JH, Kummar S. United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. Curr Probl Cancer 2013;37:110-44. [PMID: 23972982 DOI: 10.1016/j.currproblcancer.2013.06.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 592 |
Al Yaghchi C, Zhang Z, Alusi G, Lemoine NR, Wang Y. Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy 2015;7:1249-58. [PMID: 26595180 DOI: 10.2217/imt.15.90] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 593 |
Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res. 2015;21:396-404. [PMID: 25348516 DOI: 10.1158/1078-0432.ccr-14-1591] [Cited by in Crossref: 83] [Cited by in F6Publishing: 58] [Article Influence: 10.4] [Reference Citation Analysis]
|
| 594 |
Xu L, Liu YP. Advances in chemotherapy of advanced pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2010; 18(25): 2685-2689 [DOI: 10.11569/wcjd.v18.i25.2685] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 595 |
Khattak MA, Martin HL, Karapetis CS. Targeted therapy for esophagogastric cancers: a review. Onco Targets Ther 2012;5:91-102. [PMID: 22719211 DOI: 10.2147/OTT.S25117] [Reference Citation Analysis]
|
| 596 |
Perera RM, Bardeesy N. Ready, set, go: the EGF receptor at the pancreatic cancer starting line. Cancer Cell. 2012;22:281-282. [PMID: 22975369 DOI: 10.1016/j.ccr.2012.08.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 597 |
Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 2018;19:e151-60. [PMID: 29508762 DOI: 10.1016/S1470-2045(18)30098-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 598 |
Porembka MR, Mitchem JB, Belt BA, Hsieh CS, Lee HM, Herndon J, Gillanders WE, Linehan DC, Goedegebuure P. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. 2012;61:1373-1385. [PMID: 22215137 DOI: 10.1007/s00262-011-1178-0] [Cited by in Crossref: 154] [Cited by in F6Publishing: 146] [Article Influence: 15.4] [Reference Citation Analysis]
|
| 599 |
Buscail L, Bournet B, Vernejoul F, Cambois G, Lulka H, Hanoun N, Dufresne M, Meulle A, Vignolle-Vidoni A, Ligat L, Saint-Laurent N, Pont F, Dejean S, Gayral M, Martins F, Torrisani J, Barbey O, Gross F, Guimbaud R, Otal P, Lopez F, Tiraby G, Cordelier P. First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings. Mol Ther 2015;23:779-89. [PMID: 25586689 DOI: 10.1038/mt.2015.1] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 9.1] [Reference Citation Analysis]
|
| 600 |
Wang C, Zhang T, Liao Q, Dai M, Guo J, Yang X, Tan W, Lin D, Wu C, Zhao Y. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. Protein Cell. 2021;12:128-144. [PMID: 32737864 DOI: 10.1007/s13238-020-00760-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 601 |
Wong MH, Xue A, Baxter RC, Pavlakis N, Smith RC. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. Neoplasia 2016;18:425-35. [PMID: 27435925 DOI: 10.1016/j.neo.2016.06.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 602 |
Galanis E, Carlson SK, Foster NR, Lowe V, Quevedo F, McWilliams RR, Grothey A, Jatoi A, Alberts SR, Rubin J. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. Mol Ther. 2008;16:979-984. [PMID: 18388964 DOI: 10.1038/mt.2008.29] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 603 |
Stroese AJ, Ullerich H, Koehler G, Raetzel V, Senninger N, Dhayat SA. Circulating microRNA-99 family as liquid biopsy marker in pancreatic adenocarcinoma. J Cancer Res Clin Oncol 2018;144:2377-90. [PMID: 30225540 DOI: 10.1007/s00432-018-2749-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 604 |
Vijayvergia N, Cohen SJ. Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer? J Gastrointest Oncol 2016;7:727-37. [PMID: 27747087 DOI: 10.21037/jgo.2016.08.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 605 |
Ooi M, Phan A, Nguyen NQ. Future role of endoscopic ultrasound in personalized management of pancreatic cancer. Endosc Ultrasound 2017;6:300-7. [PMID: 29063873 DOI: 10.4103/eus.eus_84_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 606 |
Li K, Yang J, Chen J, Shi Y, Zhang Z, Chen W. High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. Oncol Lett 2020;19:1584-92. [PMID: 31966084 DOI: 10.3892/ol.2019.11205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 607 |
Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD. Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS One 2013;8:e58089. [PMID: 23520486 DOI: 10.1371/journal.pone.0058089] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 608 |
Fujii H, Koda M, Sadaka S, Ohata K, Kato-Hayashi H, Iihara H, Kobayashi R, Ishihara T, Uemura S, Iwashita T, Hayashi H, Sugiyama T, Shimizu M, Suzuki A. Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy - a retrospective observational study. J Pharm Health Care Sci 2021;7:27. [PMID: 34334136 DOI: 10.1186/s40780-021-00210-1] [Reference Citation Analysis]
|
| 609 |
Huang X, Li M, Hou S, Tian B. Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review). Int J Oncol 2021;59:101. [PMID: 34738624 DOI: 10.3892/ijo.2021.5281] [Reference Citation Analysis]
|
| 610 |
Seshacharyulu P, Ponnusamy MP, Rachagani S, Lakshmanan I, Haridas D, Yan Y, Ganti AK, Batra SK. Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Oncotarget 2015;6:5164-81. [PMID: 25686822 DOI: 10.18632/oncotarget.3286] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 611 |
van Duijneveldt G, Griffin MDW, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin Sci (Lond) 2020;134:2091-115. [PMID: 32808663 DOI: 10.1042/CS20191211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 612 |
Zhong A, Cheng CS, Kai J, Lu R, Guo L. Clinical Significance of Glucose to Lymphocyte Ratio (GLR) as a Prognostic Marker for Patients With Pancreatic Cancer. Front Oncol 2020;10:520330. [PMID: 33117673 DOI: 10.3389/fonc.2020.520330] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 613 |
Tong M, Wang J, Zhang H, Xing H, Wang Y, Fang Y, Pan H, Li D. Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials. J Cancer 2019;10:968-78. [PMID: 30854103 DOI: 10.7150/jca.26672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 614 |
Zeng M, Feng Q, Lu M, Zhou J, Yang Z, Tang J. Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis. Onco Targets Ther 2018;11:6633-46. [PMID: 30349297 DOI: 10.2147/OTT.S168418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 615 |
Yokoyama Y, Nimura Y, Nagino M. Advances in the treatment of pancreatic cancer: limitations of surgery and evaluation of new therapeutic strategies. Surg Today. 2009;39:466-475. [PMID: 19468801 DOI: 10.1007/s00595-008-3904-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 616 |
Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM, Lacy J. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 2013;30. [DOI: 10.1007/s12032-012-0361-2] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 617 |
Saif MW, Chabot J. Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard? Nat Rev Clin Oncol. 2011;8:452-453. [PMID: 21727930 DOI: 10.1038/nrclinonc.2011.107] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 618 |
Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 619 |
Renouf DJ, Tang PA, Major P, Krzyzanowska MK, Dhesy-Thind B, Goffin JR, Hedley D, Wang L, Doyle L, Moore MJ. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs. 2012;30:1203-1207. [PMID: 21526355 DOI: 10.1007/s10637-011-9673-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 620 |
Humphrey ES, Su SP, Nagrial AM, Hochgräfe F, Pajic M, Lehrbach GM, Parton RG, Yap AS, Horvath LG, Chang DK, Biankin AV, Wu J, Daly RJ. Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. Mol Cell Proteomics 2016;15:2671-85. [PMID: 27259358 DOI: 10.1074/mcp.M116.058313] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 621 |
Li W, Mao Z, Fan X, Cui L, Wang X. Cyclooxygenase 2 promoted the tumorigenecity of pancreatic cancer cells. Tumour Biol 2014;35:2271-8. [PMID: 24146280 DOI: 10.1007/s13277-013-1301-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 622 |
Carvajal RD, Tse A, Shah MA, Lefkowitz RA, Gonen M, Gilman-Rosen L, Kortmansky J, Kelsen DP, Schwartz GK, O’Reilly EM. A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology. 2009;9:404-409. [PMID: 19451750 DOI: 10.1159/000187135] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 623 |
Polvani S, Tarocchi M, Tempesti S, Bencini L, Galli A. Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World J Gastroenterol 2016; 22(8): 2441-2459 [PMID: 26937133 DOI: 10.3748/wjg.v22.i8.2441] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 624 |
Chen M, Yang S, Fan L, Wu L, Chen R, Chang J, Hu J. Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report. Pancreas 2019;48:1232-6. [PMID: 31609933 DOI: 10.1097/MPA.0000000000001398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 625 |
Słotwiński R, Słotwińska SM. Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer. Cent Eur J Immunol 2016;41:404-18. [PMID: 28450804 DOI: 10.5114/ceji.2016.65140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 626 |
Smith JP, Fonkoua LK, Moody TW. The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies. Int J Biol Sci 2016;12:283-91. [PMID: 26929735 DOI: 10.7150/ijbs.14952] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 627 |
Craven KE, Gore J, Korc M. Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Cancer Lett 2016;381:201-10. [PMID: 26723874 DOI: 10.1016/j.canlet.2015.11.047] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 628 |
Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial. Oncotarget 2015;6:12796-808. [PMID: 25918250 DOI: 10.18632/oncotarget.3473] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 629 |
Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, Kapoun AM, Stagg RJ, Berlin J, Messersmith WA, Cohen SJ. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs 2020;38:821-30. [PMID: 31338636 DOI: 10.1007/s10637-019-00824-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 630 |
Cheng J, Cashman JR. Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression. Invest New Drugs 2021;39:131-41. [PMID: 32915418 DOI: 10.1007/s10637-020-00998-z] [Reference Citation Analysis]
|
| 631 |
Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319-334. [PMID: 25824606 DOI: 10.1038/nrclinonc.2015.53] [Cited by in Crossref: 350] [Cited by in F6Publishing: 325] [Article Influence: 50.0] [Reference Citation Analysis]
|
| 632 |
Gao CC, Xu XL, Li F, Gong BG, Liu S, Cui YQ, Sun HC, Xu PY, Zheng YM, Jiang H. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine. Tumour Biol 2016;37:7555-64. [PMID: 26684804 DOI: 10.1007/s13277-015-4641-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 633 |
Blanco VM, Latif T, Chu Z, Qi X. Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. Transl Oncol 2015;8:196-203. [PMID: 26055177 DOI: 10.1016/j.tranon.2015.03.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 634 |
Hartley ML, Bade NA, Prins PA, Ampie L, Marshall JL. Pancreatic cancer, treatment options, and GI-4000. Hum Vaccin Immunother 2014;10:3347-53. [PMID: 25585100 DOI: 10.1080/21645515.2014.1004017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 635 |
Cheng C, Sui B, Wang M, Hu X, Shi S, Xu P. Carrier-Free Nanoassembly of Curcumin-Erlotinib Conjugate for Cancer Targeted Therapy. Adv Healthc Mater 2020;9:e2001128. [PMID: 32893507 DOI: 10.1002/adhm.202001128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 636 |
Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, Morita S, Ito T, Morimoto S, Hara K. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother. 2014;37:105-114. [PMID: 24509173 DOI: 10.1097/cji.0000000000000020] [Cited by in Crossref: 51] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 637 |
Lee SH, Chang PH, Chen PT, Lu CH, Hung YS, Tsang NM, Hung CY, Chen JS, Hsu HC, Chen YY, Chou WC. Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer. Cancer Med 2019;8:3471-8. [PMID: 31099160 DOI: 10.1002/cam4.2254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 638 |
Chen L, Ma C, Bian Y, Shao C, Wang T, Li J, Chong X, Su L, Lu J. Aberrant expression of STYK1 and E-cadherin confer a poor prognosis for pancreatic cancer patients. Oncotarget 2017;8:111333-45. [PMID: 29340057 DOI: 10.18632/oncotarget.22794] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 639 |
Wu CP, Hung TH, Hsiao SH, Huang YH, Hung LC, Yu YJ, Chang YT, Wang SP, Wu YS. Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. Cancers (Basel) 2020;12:E1366. [PMID: 32466597 DOI: 10.3390/cancers12061366] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 640 |
Sankarasubramanian S, Pfohl U, Regenbrecht CRA, Reinhard C, Wedeken L. Context Matters-Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. Front Cell Dev Biol 2021;9:760705. [PMID: 34805167 DOI: 10.3389/fcell.2021.760705] [Reference Citation Analysis]
|
| 641 |
Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs 2011;29:1057-65. [PMID: 20306339 DOI: 10.1007/s10637-010-9413-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 642 |
Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets 2012;13:811-28. [PMID: 22458528 DOI: 10.2174/138945012800564068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 643 |
Ghasemi R, Rapposelli IG, Capone E, Rossi C, Lattanzio R, Piantelli M, Sala G, Iacobelli S. Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. Oncogenesis 2014;3:e117. [PMID: 25133484 DOI: 10.1038/oncsis.2014.31] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 644 |
Padda SK, Krupitskaya Y, Chhatwani L, Fisher GA, Colevas AD, San Pedro-Salcedo M, Decker R, Latz JE, Wakelee HA. A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;69:1013-20. [PMID: 22160298 DOI: 10.1007/s00280-011-1792-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 645 |
Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer. 2013;108:1-8. [PMID: 23299539 DOI: 10.1038/bjc.2012.569] [Cited by in Crossref: 173] [Cited by in F6Publishing: 165] [Article Influence: 19.2] [Reference Citation Analysis]
|
| 646 |
Schober M, Jesenofsky R, Faissner R, Weidenauer C, Hagmann W, Michl P, Heuchel RL, Haas SL, Löhr JM. Desmoplasia and chemoresistance in pancreatic cancer. Cancers (Basel) 2014;6:2137-54. [PMID: 25337831 DOI: 10.3390/cancers6042137] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 647 |
Hofheinz RD, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, Racca P, Guenther S, Zhang J, Lacouture ME, Jatoi A. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. Oncologist. 2016;21:1483-1491. [PMID: 27449521 DOI: 10.1634/theoncologist.2016-0051] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 648 |
Kida M, Miyazawa S, Iwai T, Ikeda H, Takezawa M, Kikuchi H, Watanabe M, Imaizumi H, Koizumi W. Recent advances of biliary stent management. Korean J Radiol. 2012;13 Suppl 1:S62-S66. [PMID: 22563289 DOI: 10.3348/kjr.2012.13.s1.s62] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 649 |
Marsh Rde W, Talamonti MS, Katz MH, Herman JM. Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med 2015;4:853-63. [PMID: 25693729 DOI: 10.1002/cam4.433] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 650 |
Han H, Von Hoff DD. SnapShot: pancreatic cancer. Cancer Cell 2013;23:424-424.e1. [PMID: 23518352 DOI: 10.1016/j.ccr.2013.03.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 651 |
Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options? World J Gastroenterol 2014; 20(9): 2224-2236 [PMID: 24605022 DOI: 10.3748/wjg.v20.i9.2224] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 652 |
Mukai S, Moriya S, Hiramoto M, Kazama H, Kokuba H, Che XF, Yokoyama T, Sakamoto S, Sugawara A, Sunazuka T, Ōmura S, Handa H, Itoi T, Miyazawa K. Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. Int J Oncol 2016;48:45-54. [PMID: 26718641 DOI: 10.3892/ijo.2015.3237] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 653 |
Reznik R, Hendifar AE, Tuli R. Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma. Front Physiol. 2014;5:87. [PMID: 24624093 DOI: 10.3389/fphys.2014.00087] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 654 |
Plassmeier L, Knoop R, Waldmann J, Kesselring R, Buchholz M, Fichtner-Feigl S, Bartsch DK, Fendrich V. Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer. Langenbecks Arch Surg. 2013;398:989-996. [PMID: 23989613 DOI: 10.1007/s00423-013-1105-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 655 |
Ning Z, Xie J, Chen Q, Zhang C, Xu L, Song L, Meng Z. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients. Onco Targets Ther 2019;12:1021-9. [PMID: 30774386 DOI: 10.2147/OTT.S185424] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 656 |
Amanam I, Chung V. Targeted Therapies for Pancreatic Cancer. Cancers (Basel) 2018;10:E36. [PMID: 29382159 DOI: 10.3390/cancers10020036] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 11.8] [Reference Citation Analysis]
|
| 657 |
Hwang IG, Kang JH, Oh SY, Lee S, Kim SH, Song KH, Son C, Park MJ, Kang MH, Kim HG, Lee J, Park YS, Sun JM, Kim HJ, Kim CK, Yi SY, Jang JS, Park K, Kim HJ. Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Support Care Cancer 2016;24:301-9. [PMID: 26041481 DOI: 10.1007/s00520-015-2783-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 658 |
Ocana A, Ethier JL, Díez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget 2015;6:39538-49. [PMID: 26446908 DOI: 10.18632/oncotarget.5946] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 659 |
Saletti P, Zaniboni A. Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. J Gastrointest Oncol 2018;9:377-89. [PMID: 29755778 DOI: 10.21037/jgo.2018.01.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 660 |
Choi JH, Oh SY, Kwon HC, Kim JH, Lee JH, Lee S, Lee DM, Kim SH, Rho MH, Kim YH, Rho MS, Kim HJ. Gemcitabine versus gemcitabine combined with cisplatin treatment locally advanced or metastatic pancreatic cancer: a retrospective analysis. Cancer Res Treat 2008;40:22-6. [PMID: 19688061 DOI: 10.4143/crt.2008.40.1.22] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 661 |
Glimelius B. Any progress in pancreatic cancer? Well, but progress for Acta Oncologica. Acta Oncol 2010;49:404-6. [PMID: 20397771 DOI: 10.3109/02841861003724837] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 662 |
Tang D, Kroemer G, Kang R. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Mol Cancer 2021;20:128. [PMID: 34607583 DOI: 10.1186/s12943-021-01422-7] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 663 |
Liu HB, Wu Y, Lv TF, Yao YW, Xiao YY, Yuan DM, Song Y. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2013;8:e55128. [PMID: 23383079 DOI: 10.1371/journal.pone.0055128] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 9.1] [Reference Citation Analysis]
|
| 664 |
Wang D, Bi Y, Hu L, Luo Y, Ji J, Mao AZ, Logsdon CD, Li E, Abbruzzese JL, Li Z, Yang VW, Lu W. Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS. Cell Commun Signal 2019;17:19. [PMID: 30819189 DOI: 10.1186/s12964-019-0333-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 665 |
Lee HS, Park SB, Kim SA, Kwon SK, Cha H, Lee DY, Ro S, Cho JM, Song SY. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. Sci Rep 2017;7:41615. [PMID: 28134290 DOI: 10.1038/srep41615] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 666 |
Abbassi R, Algül H. Palliative chemotherapy in pancreatic cancer-treatment sequences. Transl Gastroenterol Hepatol 2019;4:56. [PMID: 31559337 DOI: 10.21037/tgh.2019.06.09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 667 |
Vucetic M, Daher B, Cassim S, Parks S, Pouyssegur J. Overcoming Therapeutic Challenges for Pancreatic Ductal Adenocarcinoma with xCT Inhibitors. Adv Exp Med Biol 2021;1301:7-24. [PMID: 34370285 DOI: 10.1007/978-3-030-62026-4_2] [Reference Citation Analysis]
|
| 668 |
Kruger S, Haas M, Ormanns S, Bächmann S, Siveke JT, Kirchner T, Heinemann V, Boeck S. Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts. World J Gastroenterol 2014; 20(31): 10769-10777 [PMID: 25152580 DOI: 10.3748/wjg.v20.i31.10769] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 669 |
Pothula SP, Xu Z, Goldstein D, Biankin AV, Pirola RC, Wilson JS, Apte MV. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. Br J Cancer. 2016;114:269-280. [PMID: 26766740 DOI: 10.1038/bjc.2015.478] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 670 |
Lamarca A, Feliu J. Pancreatic biomarkers: Could they be the answer? World J Gastroenterol 2014; 20(24): 7819-7829 [PMID: 24976720 DOI: 10.3748/wjg.v20.i24.7819] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] |
